Atrial Fibrillation and Stroke:

State-of-the-art and future directions

Sandra Elsheikh,1,2,3† Andrew Hill,1,3 Greg Irving,1,4

Gregory Y.H. Lip,1,2,5\* Azmil H. Abdul-Rahim1,2,3\*

# Affiliations:

1. Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
2. Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
3. Mersey and West Lancashire Teaching Hospitals NHS Trust, St Helens, UK.
4. Health Research Institute, Edge Hill University Faculty of Health and Social Care, Ormskirk, UK.
5. Danish Centre for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

**\***Joint senior authors

**†**Corresponding Author:

Sandra Elsheikh

Liverpool Centre for Cardiovascular Science, Cardiovascular and Metabolic Medicine, University of Liverpool

Address: University of Liverpool, 6 West Derby Street, Liverpool, L7 8TX

Tel: 0151 430 1176

E-mail: [s.elsheikh2@liverpool.ac.uk](mailto:s.elsheikh2@liverpool.ac.uk)

# Abstract

Atrial fibrillation (AF) and stroke remain a major cause of morbidity and mortality. The two conditions shared common co-morbidities and risk factors. AF-related strokes are associated with worse clinical outcomes and higher mortality compared to non-AF-related. Early detection of AF is vital for prevention. While various scores have been developed to predict AF in such a high-risk group, they are yet to incorporated into clinical guidelines. Novel markers and predictors of AF including coronary and intracranial arterial calcification have also been studied. There are also ongoing debates on the management of acute stroke in patients with AF, and those who experienced breakthrough stroke while on oral anticoagulants. We provided an overview of the complex interplay between AF and stroke, as well as the treatment and secondary prevention of stroke in AF. We also comprehensively discussed the current evidence and the ongoing conundrums, and highlighted the future directions on the topic.

# Keywords:

atrial fibrillation (AF), stroke, oral anticoagulant (OAC), thrombolytic therapy, left atrial appendage occlusion

**(Word count:** **11850)**

# Introduction

Stroke is a major complication of atrial fibrillation (AF). About 25% of ischaemic stroke are cardio-embolic in origin; AF is the most common cause of those[1]. Nonvalvular AF carries a 5-fold increased risk of stroke[2], while AF related to mitral stenosis increases the risk of stroke by 20-fold[3]. The attributable risk of stroke for AF increases with age unlike other factors such as hypertension for instance[4].

When the AF is asymptomatic but detected on a cardiac implantable electronic device (CIED) or a wearable monitor, it is described as being subclinical. It is suspected that subclinical AF might be the cause of cryptogenic strokes (i.e., strokes of unknown aetiology)[5]. While previous studies showed that atrial high-rate events (AHREs) detected on a CIED were associated with increased risk of stroke[5,6], treating such episodes with anticoagulation has not been shown to reduce the risk of stroke. In fact, anticoagulation in these cases resulted in higher incidence of a composite of death or major bleeding, mainly driven by the increased risk of bleeding[7].

Not only that AF can cause stroke and vice versa[8], but stroke patients with AF were shown have higher stroke severity and mortality compared to those without[9]. The effect of AF on mortality rate was primarily driven by stroke severity[9]. The worse clinical and imaging outcome in AF-related strokes was attributed to bigger volumes of more severely hypo-perfused tissues, resulting in larger infarct size and higher risk of haemorrhagic transformation[10].

In this narrative review article, we provided an overview of the burden of AF and stroke, the complex interplay between the two conditions, as well as the treatment and secondary prevention of stroke in patients with AF. We comprehensively discussed the current evidence and the ongoing conundrums, and highlighted the future directions on the topic.

# Epidemiology

## Atrial fibrillation

Atrial fibrillation (AF) is the most common cardiac arrhythmia[11,12], and one of the most common cardiovascular conditions in men and women[12]. Its prevalence (1–2% of the total population) continues to increase with advancing age, reaching around 10% in those above 75 years of age[12]. It remains a major cause of morbidity and mortality, with an estimated five million incident cases globally[13]. Approximately eighteen million of people in Europe are estimated to have AF by 2060[11].The condition is therefore considered an epidemic[14,15] and a major public health challenge.

There are interracial differences in the incidence and prevalence of AF[3,16–18]; with higher rates seen in European descendance individuals compared to Asians and those of African descendance (despite the higher burden of comorbidities seen in the latter)[3,17]. These observations were also recorded in the Analysis of the Atherosclerosis Risk in Communities (ARIC)[18] study where African-Americans had a 41% lower adjusted risk of developing AF compared to whites. Factors such as limited access to health care with resultant lower AF detection rates, more frequent paroxysmal AF, and evidence of smaller left atrium size in African-Americans were suggested as an explanation for their lower incidence of AF compared to similar age adjusted white population[17]. Genetic predisposition was another hypothesis put to explain the interracial differences. In a meta-analysis by Marcus et al. [19], the cohort of whites and African-Americans in the Cardiovascular Health Study (CHS)[20] and ARIC Study[18] were reviewed, and the percentage European ancestry in African-Americans was calculated with 1747 ancestry informative markers from the Illumina custom ITMAT-Broad-CARe array. The meta-analysis found that for every 10% increase in European ancestry, the risk of AF increased by 13%[19]. This trend persisted even after correction for potential confounders, indicating a clear role of genetic variants in development of AF. A difference in mortality between ethnic groups might account for some of the discrepancy in AF prevalence between them: both all-cause and cardiovascular disease mortality are higher among African-Americans compared to whites, leaving a disproportionate smaller African-American population surviving to be at risk of developing AF[18].

In the Framingham Heart Study population, the lifetime risk of developing AF was estimated to be 1 in 4 for men and women at an index age of 40 years or older[21]. The lifetime risk for developing AF remained high at 1 in 6 even in the absence of prior or concurrent known history of myocardial infarction or congestive heart failure[21]. In 2017, the estimated number of individuals with AF/flutter globally was 19.8 million men (95% uncertainty interval (UI) 17.2-22.4 million) and 17.8 million women (95% UI 15.3-20.2 million)[22].

The Global Burden of Disease (GBD) report confirmed the increasing prevalence of AF over the years. By 2019, the prevalence of AF and atrial flutter appears to have increased by more than double (+120.7%) since 1990 with the larger growth registered in middle-income countries (+146.6% in lower-middle- and +145.2% in upper-middle-income countries)[23]. The absolute global prevalence of AF/ atrial flutter reached nearly 60 million of cases in 2019 compared to about 28 million of cases in 1990[23]. A few factors have been suggested to explain this trend; including an increased incidence of hypertension particularly in low-, lower-middle-, and upper-middle-income countries, as well as increased incidence of obesity in all income groups[15,23]. Another theory is improved management strategies for cardiovascular conditions closely related to AF, such as heart failure and ischaemic heart disease, resulting in surviving aging population at high risk of developing AF[15]. Improving AF diagnosis and detection rates is another contributing factor[15,24].

The financial burden of AF on public health is considerable. The cost of AF to health and social services, including that of outpatient and general practitioner consultations, hospitalization and drug treatment (including the cost of anticoagulation treatment and monitoring) was first evaluated in the UK in 1995[25]. In 2000, Stewart et al. used contemporary and extrapolated data[25] and estimated that the direct cost of AF during 2000 (excluding nursing home costs and admissions with a secondary AF coding) was £459 million, 0.88% of total National Health Service (NHS) expenditure[25].This figure does not consider related conditions such as aspirin or warfarin related brain haemorrhage, stroke rehabilitation, or digoxin toxicity[25]. It has been predicted that between 0.9% and 1.6% of NHS expenditure in 2020 was on AF, mostly from primary admissions. The predicted direct cost spent in the NHS on AF is £1,435 m-£2,548 m (depending on AF prevalence). The total direct costs of AF are expected to increase to 1– 4% of NHS expenditure over the next two decades[26].

Alongside increasing age, a few chronic conditions have been linked to the development and increased risk of AF including the following: hypertension, diabetes, heart failure, ischaemic heart disease, valvular disease, hyperthyroidism, obesity, alcohol consumption, chronic kidney disease and lung diseases[3,17,27].

## Stroke

Three main pathological domains fall under the umbrella term “Stroke”, and these are: ischaemic strokes (87%), intracerebral haemorrhage (ICH) (10%), and subarachnoid haemorrhage (SAH) (3%)[28][29].

Stroke is the most common neurological disease[30] and the second most common cause of death globally[28,30]. It has a lifetime risk of at least 1in 6[30]. It is a major cause of disability, and accounted for about 116 million global disability adjusted life-years (DALYs) lost in 2016(40). In 2016, the global stroke prevalence was 80.1 million (95% confidence interval [CI] 74.1–86.3), with higher female prevalence (41.1 million (38.0–44.3)) compared to male[29]. In the same year, the number of incident new strokes raised to 13.7 million (95% CI 12.7–14.7); 87% of these were ischaemic strokes(40). In 2017, stroke prevalence increased by 19.3%, incidence by 5.3%, disability-adjusted life-years by 2.7%, and mortality by 5.3%(42). It is projected that by 2030, 3.9% of the adult population in the US would have had a stroke and absolute stroke mortality would increase by 50%, translating to 64,000 additional stroke deaths per year compared to 2012(40).

There is also an ethnic variation in the stroke incidence, that is, 1.91 per 1,000 in African-American population vs 0.88 per 1,000 in the white population(40). This racial variation is also seen in the distribution of ischaemic stroke subtypes: large artery atherosclerosis is the leading cause of ischaemic stroke in the Asian population (33%), while cardio-embolism is the leading cause in the white population (28%)(40).

Variation in availability of resources worldwide also bears an effect on the stroke burden and outcomes, for example, the stroke case-fatality rate at 30 days ranged from about 10% in Dijon, France (2000-2004) to as high as 42% in Kolkata, India (2003-2010)(40). In addition, the age at first stroke tends to be lower in low- and middle-income countries, resulting in the relatively higher proportion of strokes and the higher burden of DALYs lost in the developing world.(40).

# Ischaemic stroke subtypes

Multiple studies have looked into classifying strokes. Subtyping strokes is useful for clinical, epidemiological and genetic studies, and can serve classifying patients for therapeutic decision-making in daily practice[32]. In addition, stroke outcomes, including recurrent stroke, and strategies for secondary stroke prevention differ by stroke subtype(44).

The Harvard Cooperative Stroke Registry[34] was formed in 1972. The initial report from the prospective registry was published in 1978 and included 694 patients. Among those, 233 patients were given a diagnosis of thrombosis of a large artery, 131 were diagnosed with lacunes, 215 with embolism, 70 with intracranial hematoma, and 45 with aneurysm-arteriovenous malformation. However, only a small percentage of those patients had angiography or computed tomography (CT) (106 patients of those diagnosed with embolic stroke had angiography and only 49 of them had CT)[34].

In 1989, a classification of stroke according to causal mechanisms, the Stroke Data Bank [35], was developed. While strokes due to haemorrhage included parenchymal haemorrhage and subarachnoid haemorrhage, strokes due to infarction included: large-artery atherosclerosis, lacune, cardio-embolic, infarction with tandem arterial pathology, and infarction of undetermined cause or infarction with a normal angiogram[35]. A CT scan was documented in 98% of patients with infarction and angiography was performed in 27%. The strict diagnostic scheme used helped identifying stroke subtypes that would have otherwise been classified as infarcts of undetermined cause (IUC). Nevertheless, 28.1% of total strokes (39.9% of infarcts) in the study were still classified as IUC[35].

The Trial of Org 10172 in Acute Stroke Treatment, (TOAST) system[36] was proposed in 1993, classifying ischaemic strokes into large-artery atherosclerosis, cardio-embolism, small-vessel occlusion (lacunes), stroke of other determined aetiology (such as non-atherosclerotic vasculopathies, hypercoagulable states, or haematological disorders), and stroke of undetermined aetiology (which also includes patients with two or more potential causes of stroke). Besides the use of clinical features and brain imaging (CT or magnetic resonance imaging [MRI]), arteriography, cardiac imaging (such as echocardiography), duplex imaging of extracranial arteries, and laboratory assessments for a pro-thrombotic state were also used to reach a diagnosis. Without supportive findings on diagnostic testing, a diagnosis of a specific subtype of stroke could not be made based on suggestive historical and physical features. Such strict rules increased the specificity of the system reducing the likelihood of misclassification at the expense of decreased sensitivity and increased number of strokes classified as strokes of undetermined aetiology[36].

In 2005, the Stop Stroke Study TOAST (SSS-TOAST) system[33] was designed based on the original TOAST algorithm. Each causative category within the TOAST system was subdivided based on the weight of evidence as “evident, (when one stroke mechanism adhering to a single causative category was identified),” “probable, (when more than one “evident” stroke mechanisms were identified, but one mechanism seemed more probable than the other based on certain characteristics),” or “possible (when no evident cause has been identified).” The main 5 mechanisms of ischaemic stroke according to this algorithm include: large artery atherosclerosis,cardio-aortic embolism,small artery disease,other causes, or undetermined causes. Under the category of undetermined causes two subtypes were identified: cryptogenic strokes (where no “evident” or “possible” criteria for the other causes have been identified) or unclassified (when there is more than one evident mechanism but with probable evidence for each or with no probable evidence to be able to establish a single cause). This classification improved the interobserver reliability (kappa (κ) value) of the original TOAST from 0.78 to 0.90, and reduced the number of patients originally assigned to the “undetermined-unclassified” class by the original TOAST system from 38–40% to 4%[33]. The computerised automated version of the SSS-TOAST system was released in 2007 and is known as the Causative Classification System (CCS)[37].

Both TOAST and CCS limited large artery disease to patients with carotid stenosis and did not consider high plaque burden (measured by total plaque area)[38]. Total plaque area is known to be a stronger predictor of poor outcomes (including stroke, MI and death) than stenosis measured by Doppler velocities[39]. The combined 5-year risk of stroke, MI, and vascular death was 19.5% when the carotid plaque area was 1.19 to 6.73 cm2(51). Published in 2014, Bogiatzi et al. developed the Subtypes of Ischaemic Stroke Classification System (SPARKLE) as an adaptation of the SSS-TOAST that included total plaque area measurements in the definition of large artery atherosclerosis[38]. This reduced the number of strokes previously classified as of an undetermined aetiology allowing for more specific treatment of underlying causes. Eighteen patients with large artery disease in SPARKLE were classified as undetermined in SSS-TOAST and TOAST (**Figure 1**)[38]. Also, 131 cases with either multiple causes of stroke/TIA or high total plaque area without carotid stenosis and otherwise large artery disease in SPARKLE were classified under the undetermined category in TOAST. This classification showed a substantial inter-rater reliability (κ = 0.76) and an excellent rater consistency over time (κ = 0.91)[38].

# Stroke as a cause of AF

Associations between abnormal autonomic innervation and AF have been established(67), and insults to the central nervous system (as in stroke) are believed to play an important role in the pathogenesis of AF(58). In the acute post-stroke period, various forms of electrocardiographic and arrhythmic changes, including AF are detected.

AF is diagnosed in about 7% of patients with acute ischemic stroke within the first 3-5 days post-stroke[42]. The percentage of diagnosed AF increases to 25% with prolonged cardiac monitoring [43]. This has recently been termed AF diagnosed after stroke (AFDAS)[44]. Various studies have previously focused on AF as a previously undetected arrhythmia and failed to appreciate AF as a consequence of stroke. The earlier the appearance of AF post-stroke suggests that it might be a consequence of rather than a cause of stroke [45]. However, less incidence of AF post-haemorrhagic stroke doesn’t support this notion. Signs of cardiac involvement are usually lacking in those who develop AF as a result of stroke. One study found that AFDAS was associated with less recurrent stroke (6.6%) compared to those with previous diagnosis of AF (9.6%)[46]. More recently, a retrospective, registry-based cohort study[47] classified AFDAS into two different categories: ECG-detected AF and AF detected on a prolonged cardiac monitor [PCM-detected AF] (which is usually asymptomatic and of lower burden). The differences in the baseline characteristics between ECG- and PCM-detected AF in this study resembled those found between known AF and AFDAS. Furthermore, ECG-detected AF in this study was associated with 5-fold higher adjusted recurrent ischemic stroke risk compared to PCM-detected AF. This suggests that ECG-detected AF is likely pre-existent but hadn’t been diagnosed before the stroke due to the lack of symptoms or the insufficient interaction with the health care system[47].

Several mechanisms have been postulated for the development of AF post-stroke:

There is evidence that development and maintenance of AF is linked to imbalances in cardiac autonomic nervous system (ANS), particularly following acute stroke. A disruption of regulation of heart rate and blood pressure leading to increased cortisol and catecholamines levels is a contributor[48]. ANS imbalance after stroke mainly manifests as sympathetic overactivation and may contribute to development of AF.

Location of the stroke within the brain has been shown to be associated with development of AF. Insular cortical damage is associated with 7-fold increased risk of AF[49][50]. Other locations of stroke have been linked to occurrence of AF post stroke including periaqueductal grey matter, hypothalamus, amygdala and other locations. While these locations are thought to produce AF via affecting ANS, the exact mechanism linking certain brain locations to development of AF is not known[45].

Additional mechanism leading to AF occurrence post stroke involves a ‘catecholamine surge hypothesis’. Catecholamines released from adrenal glands and sympathetic system lead to higher occurrence of arrhythmias.

More recently, the entity of Stroke-Heart syndrome has been recognized[42]. Stroke-Heart syndrome manifestations tend to be transient, however, both short and potentially long-term outcomes can be poor for a subgroup of patients [42]. This syndrome encompasses all of the mechanisms described above; however, more evidence is required to delineate its exact pathophysiology and identify therapeutic targets to enable individualised patient care[42].

Acute ischaemic stroke is known to induce an inflammatory response both at the myocardial and systemic levels. Changes in the atria at the molecular and structural level have been detected, both in animal and human models. Multiple cytokines and inflammatory mediators such as tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 are overexpressed leading to systemic inflammation[45][51].

Finally, AFDAS is a complex entity, and until further evidence is available, patients with AFDAS should receive anticoagulation as per current clinical practice[51].

# Mechanisms of stroke in AF

While AF is an independent risk factor for stroke[52], the biological gradient between AF burden and stroke risk is not well established(61). In older patients with vascular risk factors, an episode of subclinical AF increases the risk of stroke by 2-fold(55), while clinically apparent AF in young and otherwise healthy individuals with CHA2DS2-VASc score of 0 does not seem to pose a clinically important increase in stroke risk(62).

One of the proposed mechanisms of stroke in AF is that the impaired atrial contractility seen in AF leads to uncoordinated myocyte activity with resulting stasis and increased risk of thromboembolism[53]. Nevertheless, the evidence suggests the absence of survival benefit or difference in stroke risk between those treated with rhythm control or rate control strategies[55][56]. Hence, dysrhythmia and resultant stasis and thrombosis cannot be the only mechanism of stroke in AF. On the other hand, early rhythm control in selected patients with recent onset AF appears to be associated with improved clinical outcomes compared to usual care[57]. The Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST AFNET 4) was an international, investigator-initiated, parallel-group, open, blinded-outcome assessment trial, which randomised AF patients diagnosed within a year of enrolment to rhythm control or usual care. This trial included 2789 patients, and its primary end point was a composite of death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome. The primary outcome occurred less in patients assigned to early rhythm control. Notably, this trial was stopped at the third interim analysis for efficacy at 5.1 years follow up. Baseline characteristics were equal between groups, and treatments received were equal too. In comparison to previous trials, EAST AF-NET 4 enrolled patients with a new diagnosis of AF, more than half of which were in sinus rhythm when they entered the study[57].

Aortic arch atheroma often found in AF patients have also been associated with increased risk of stroke, and increased risk of stroke in AF may partially represent embolism from undetected aortic arch lesions[58]. However, not all AF-related strokes are embolic; in the study by Loddler et al.(64) AF was prevalent in 10% of patients with lacunar infarcts thought to be non-cardioembolic, arising from the occlusion of a single perforating artery.

The interplay between AF and stroke is complex (**Figure 2**)[8]. While abnormalities of atrial substrates such as endothelial dysfunction, fibrosis, impaired myocyte function, chamber dilatation, and mechanical dysfunction in the left atrial appendage are often seen in AF, they have also been found associated with stroke risk independently of AF. This suggests that AF might in fact be a lagging marker of atrial abnormality(63).

In addition, comorbidities associated with increased risk of AF, such as hypertension, diabetes, congestive heart failure, dyslipidaemia, coronary heart disease, sleep apnoea, tobacco and obesity[3,17,27], have also been established as risk factors for stroke(66). Such systemic vascular risk factors result in an abnormal atrial substrate or atrial cardiomyopathy, and this itself can cause both AF and thromboembolism. Once AF develops, the atrial contractile function, and subsequently the underlying atrial cardiomyopathy worsen, increasing the thromboembolic risk and explaining the increase in stroke risk after the onset of AF(63).

# Cardio-embolic stroke, cryptogenic stroke and embolic stroke of undetermined source (ESUS)

A significant overlap has been noted between the above three clinical terms but they are not synonymous.

## Cardio-embolic stroke

In a prospective study using the TOAST criteria, cardioembolic strokes were found to account for about one third of ischaemic strokes(90). High risk sources of cardiac-embolism include: AF or atrial flutter, mechanical prosthetic valves, rheumatic heart disease, infective endocarditis, left atrial or ventricular thrombus, recent MI (<4 weeks), dilated cardiomyopathy, regional left ventricular akinesis, atrial myxoma, and patent foramen ovale (PFO) with thrombus in situ(63).

Clinically, cardio-embolic strokes are classically characterised by sudden onset of maximal neurological deficit, and the presence of cortical signs such speech disturbances and visual field defects(63,91). Decreased level of consciousness is also a predictor of embolic stroke(91,92).

From a neuro-imaging perspective, infarct pattern and distribution can give aetiological clues; e.g., infarcts along the borders between brain artery territories suggest systemic hypotension or multiple emboli, and a small deep infarct along with white-matter hyperintensities suggests intrinsic small-vessel disease(93). Tomographic features supportive of embolic stroke also include: the presence of a low-density zone corresponding to the territory of a single cerebral surface branch of a major cerebral artery(92), infarcts of different ages in a single territory (suggesting emboli of arterial origin)(93), evidence of cerebral or cortical infarct(45,92), or the presence of multiple territory acute infarcts(45)(suggesting emboli from a proximal aorto-cardiac source(93)). When angiography is performed, an abrupt vessel cut-off without significant atherosclerotic narrowing of the upstream vessel(63).

Previous studies suggested that recurrent embolism to the brain occurs within 2 weeks of an initial cardioembolic stroke in 10-20% of the cases(94). Immediate anticoagulation in this population has been controversial. The Cerebral Embolism Group showed a trend toward reduction of recurrent embolism with the use of early anticoagulation in this group in the absence of hypertension or evidence of haemorrhage on CT performed 24-48 hours after stroke(94).

## Cryptogenic stroke

Cryptogenic stroke often refers to an ischaemic stroke where no probable cause has been identified despite adequate diagnostic work up(93). The term is also used to describe strokes with incomplete evaluation(63,93), and extends to include strokes where two or more plausible causes are found that the physician is unable to make a final diagnosis(48). It accounts for 10-40% of ischaemic strokes(93). Attempts to identify the mechanism(s) of stroke in this group is important for planning treatment strategy and secondary prevention(95).

Routine diagnostic work-up usually includes: echocardiography, inpatient cardiac telemetry or Holter monitoring, MRI or CT imaging, and MR or CT angiographic assessment of neck and brain arteries. More specialised tests reveal the cause of “cryptogenic” stroke in more than half of those cases(93). Such causes include occult atherosclerosis (such as non-stenosing but unstable plaques at intracranial and cervical sites or stenosing plaques at the thoracic origins of the common carotid and thoracic vertebral arteries); non-atherosclerotic arteriopathies, such as dissection or vasculitis; hypercoagulable states; cardio-embolism from medium-grade sources, such as low-burden paroxysmal atrial fibrillation or dilated cardiomyopathy of moderate degree; or paradoxical embolism(93). Covert AF has been detected in 10-20% of patients with cryptogenic stroke who underwent extended (7-30 days) cardiac rhythm monitoring. However, the duration of paroxysmal AF was brief in many patients to justify the use of anticoagulation with certainty(96).

## Embolic stroke of undetermined source (ESUS)

The term ESUS was introduced in 2014 to describe cryptogenic strokes that are likely caused by embolism after the exclusion of major-risk cardioembolic sources, proximal occlusive atherosclerosis, and lacunar strokes due to cerebral small artery disease (96). While antiplatelets are recommended for cryptogenic strokes, the subset of ESUS is likely to benefit from anticoagulation(96).

ESUS comprises 1 in 6 of all ischaemic strokes, with an annual stroke recurrence rate of about 4.5%(97). In the systematic review by Hart et al., ESUS patients were younger (with mean age 65 years), had lower rates of conventional vascular risk factors than non-ESUS patients with ischaemic stroke, and 42% were women(97). A certain stepwise approach has been suggested to reach a diagnosis of ESUS (**Figure 3**)[67,68].

While multiple trials found that AF may be detected in 30% of ESUS patients, its causal association with stroke remains uncertain(98). This was supported by the findings of the Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED) trial, where among patients with cryptogenic stroke, there was no significant difference in the recurrent stroke rates between the intervention group (who had enhanced and prolonged monitoring, yielding AF detection rate of 13.5% at 12 months) and the control group (who received stroke-unit telemetry for a median duration of 73 hours +/-additional Holter-ECG-monitoring for a median of 24 hours, yielding an AF detection rate of 6.1%)(99).

## The role of patent foramen ovale (PFO) in cryptogenic stroke/ ESUS

PFO is the most common cause of a right-to-left cardiac shunt(93). It affects 25% of the adult population and is found in nearly 50% of patients with cryptogenic stroke (93,100,101).  Nevertheless, not all patients with PFO develop stroke; and PFO is thought to be the likely the cause of approximately 5% of all ischemic strokes and 10% of those occurring in young and middle-aged adults(102).

It is presumed that the paradoxical embolus passing from the right to the left atrium through a PFO results in stroke(98,101). However, the absolute risk of stroke recurrence in PFO patients receiving medical therapy alone was low (1.27 per 100 person‐years), and no higher risk of stroke recurrence was observed in patients who received antiplatelets only as opposed to oral anticoagulants (1.33% versus 1.30%)(103).

The Risk of Paradoxical Embolism (RoPE)(104) score was developed to assess the causality of PFO in cryptogenic strokes. It was validated in a multicentre study to predict the presence/absence of PFO in patients with ESUS, and subsequently identifying a likely pathogenic PFO which may benefit from closure. This study(104) also showed that patients with low RoPE score / incidental PFO had significantly higher rates of new incident AF (similar to those without PFO), while those with pathogenic PFO had a very low rate. A PFO frequency of >60% was noted in patients with a RoPE ≥7, translating to a PFO-attributable fraction >80%(104).

Evidence suggests that PFO closure is may be superior to antithrombotic therapy with regard to the risk of stroke recurrence in patients of ≤60 years of age with cryptogenic stroke(103).

# Considerations on AF-related stroke risks

## Does the patterns of AF matter?

AF is considered paroxysmal AF when episodes last <7 days and spontaneously revert to normal sinus rhythm, persistent when they last ≥7 days, or permanent when AF rhythm is accepted and no further attempts to achieve normal sinus rhythm are made[76].

The role of AF pattern (paroxysmal, persistent or permanent) in relation to stroke risk has been the subject of controversy, as trials have shown conflicting evidence[77][78][79]. The analysis of incidence of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A and AVERROES databases[77] showed that after adjusting for other independent risk factors, persistent and permanent AF has about two-fold higher rate of stroke or systemic embolism than paroxysmal AF. Similar findings were reported in other trials such as the ARISTOLE trial[78]. On the other hand, in the Stroke Prevention in Atrial Fibrillation (SPAF) studies, where patients treated with aspirin for intermittent AF and for sustained AF were assessed, stroke rates were found similar between both cohort groups[79].

## Does AF duration matter?

(80)(81) of non-sustained AF episodes (defined as short-lasting <30-second-long irregular runs of supraventricular tachycardia) in stroke has not been proven yet[80]. In the retrospective study by Arvasa et al.[80] the rates of non-sustained AF were not higher in patients with cryptogenic strokes compared with those with other causes of stroke.

On the other hand, studies using data from implantable pacemakers suggest increased rates of embolic complications with total AF burden of >5 minutes, and even higher risk when the burden is >24hours[81][82]. In The Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT), subclinical atrial tachyarrhythmias (at heart rate of at least 190 beat per minute (bpm) for more than 6 minutes) detected on pacemakers/ implantable cardioverter defibrillators (ICD) independently increased the risk of ischaemic stroke or systemic embolism by 2.5-fold with a trend towards higher risk when the episodes are longer in duration[5]. Similarly, in the Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST)[6], atrial high-rate events (AHREs) lasting more than 5 minutes in patients with sinus node disease (SND) who had received pacemakers were associated with increased risk of stroke as well as death. These patients were also 6 times more likely to develop AF compared to those without documented AHREs[6]. Treating patients with documented AHREs of at least 6 minutes with Edoxaban did not reduce the risk of stroke despite the inclusion of patients ≥,65 years of age with additional one or more risk factor for stroke. Furthermore, Edoxaban at stroke prophylaxis dose in these patients resulted in increased risk of major bleeding[7].

This suggests that the targets in AF therapy should be lower AF burden, less frequent episodes, and shorter AF duration.

## Is rhythm control strategy better than rate control strategy?

Previously, various studies have looked into the difference in outcomes between rate control strategy and rhythm control strategy for treatment of AF and showed comparable outcomes between the two strategies[55][83][84][85][86][87]. In an intention-to-treat analysis of the results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study[55], patients with AF at high risk of stroke or death who were treated with rhythm strategy had no survival benefit over those treated with rate control strategy. There was no difference in the incidence of stroke between the two study groups. The study also confirmed that anticoagulation (warfarin was used in this trial) reduced the risk of stroke in high-risk AF patients even when sinus rhythm had been restored and maintained. In a post-hoc analysis of the same trial using an “on-treatment analysis”, the presence of sinus rhythm (when analysed as a separate variable to the use of antiarrhythmic drugs (AADs)) was also associated with reduced risk of death[83].

Even in patients with congestive heart failure, previous data showed that a rhythm control strategy did not reduce the risk of stroke or death from any causes[84]. Similarly, for post-operative new onset AF, rhythm control had no advantage over rate control strategy with regards to complication rates[85].

More recently, the EAST AFNET 4 trial [88] examined if early rhythm control (ERC) (defined as AF diagnosed within <12 months) would result in better outcomes compared to usual care. This trial, which enrolled ﻿2789 patients with a median time of 36 days from AF diagnosis, showed a significant reduction in its primary outcome (a composite of death from cardiovascular causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome) in favour of ERC versus usual care based on the current evidence-based AF treatments. Unlike previous trials of rhythm control, the EAST AFNET 4 used AF catheter ablation as well as AADs for rhythm control. The improved outcomes seen with ERC in this trial are attributable to the use of catheter ablation, the use of rate control therapies in both arms of the trial, the use of anticoagulation, as well as the management of comorbidities according to current standard practice guidelines.

Efficacy of ERC has been tested in several prespecified subgroup analyses of the EAST AFNET 4 trial. In patients with symptoms or signs of heart failure, ERC conferred benefit regardless of ejection fraction status[89]. Another prespecified subgroup analysis of the trial included patients with high comorbidity burden (defined as those with CHA2DSsVSc ≥ 4), in whom ERC should be considered as concluded. Those with less comorbidities were shown to derive less benefit from ERC[90]. The incurred benefit from ERC seen in the EAST AFNET 4 trial was also noted regardless of the AF pattern (i.e., first diagnosed, paroxysmal or persistent AF)[91].

The current European Society of Cardiology guidelines for the diagnosis and management of AF recommend rhythm control in patients with symptomatic AF[92], a recommendation which was mainly based on the lack of benefit from rhythm versus rate control based on earlier studies. In a separate sub-analysis of the EAST AFNET 4 trial, the primary outcome was not different between asymptomatic (those with European Heart Rhythm Association [EHRA] score of 1) and symptomatic patients, suggesting that ERC should be discussed with all patients regardless of their symptom status[93]. It should be noted that the baseline characteristics and the rhythm control methods used were found comparable between the above analysis groups.

In a sex-based analysis of the EAST AFNET 4, no significant differences were demonstrated in the primary outcome based between males and females[94]. When sub-analysis was performed taking prior stroke status into account, the positive impact of ERC was maintained[95]. When genotyping was performed and polygenic risk scores were calculated for both AF and ischemic stroke, ERC was still found to be effective among the various genetic AF and stroke risk arrays[96]

### Real-world data: rhythm control versus rate control

An observational study utilizing the National Health Claims Database (NHIS-2016-4-009) provided by the National Health Insurance Service (NHIS) of Republic of Korea for the period 2005-2015 was published in 2023. The population observed was similar to that of the EAST AFNET 4 trial, and included patients (total 20,611) who received rhythm or rate-control therapies within 12 months of AF diagnosis. The impact of frailty on outcomes of early rhythm control was assessed. The primary end point (a composite outcome of cardiovascular-related mortality, myocardial infarction, hospitalization for heart failure, and ischemic stroke) was lower in the early-rhythm control group who were non-frail, and a signal toward a lower risk of early rhythm-control was observed in the moderately frail

and highly frail individuals[97].

When assessing the impact of sex on outcomes in the same Korean database population, rhythm control compared to rate control was associated with lower risk of the described primary composite outcome in both sexes. However, the observed relative benefit was attenuated gradually in women and remained steady in men until 12 months[98].

When assessing the effect of early rhythm-control strategy for AF in a UK based population, using the UK BioBank database, 22,650 participants out of 28,174 with new diagnosis of AF of <1 year were eligible after applying the EAST AFNET inclusion and exclusion criteria. 12,329 were later excluded due to insufficient follow up data for outcome analysis. The composite efficacy outcome of cardiovascular death, stroke/transient ischemic attack (TIA) or hospitalization for worsening heart failure or acute coronary syndrome, and the composite safety outcome (stroke, death or serious adverse event related to rhythm control therapy) were significantly lower in the early rhythm-control group before propensity score matching of the study cohorts was performed. However, the matched analysis showed no difference between the compared groups in the primary efficacy or safety outcomes. Hence, it appears that early rhythm-control strategy for AF is safe in routine care[99].

In a European cohort of 10,707 AF patients derived from the EHRAESCEORP-AF General Long-Term Registry, the generalizability of the EAST AFNET 4 results was evaluated. Only 34% of this population met the eligibility criteria as stated in the EAST AFNET trial. While early rhythm control strategy was associated with higher use of health-care resources, it resulted in significantly lower rates of primary outcome (including cardiovascular death, stroke, acute coronary syndrome, and worsening of heart failure). This difference was not statistically significant in the fully adjusted analyses, suggesting that differences in baseline characteristics may have played a role in the initial outcome results[100].

The positive outcomes of early rhythm control strategy of the EAST AFNET 4 trial were also mirrored in the retrospective analysis by Dickow et al. which included 109,739 AF patients from the US administrative database, 72.9% of which met the EAST AFNET eligibility criteria[101].

In a systematic review and a meta-analysis of 5 pooled observational studies, early rhythm control strategy resulted in significantly reduced risk of a primary composite outcome of death, ischemic or haemorrhagic stroke, hospitalization with heart failure, or acute coronary syndrome. In addition, no significant interactions between RCT and real-world data regarding outcomes were observed[102].

Thus, unlike previous trials, EAST AFNET 4 trial as well as recent observational studies based on real-world patients’ database are in favour of early rhythm-control strategy over rate-control strategy.

## Sex differences in stroke risk in AF

AF is associated with a 1.5-1.9-fold increase in mortality in both sexes. Even though the conferred mortality risk with AF does not seem to increase with age, there is a clear discrepancy in the AF impact on mortality between sexes, and females seem to be more disadvantaged[103].

Female sex is also strongly associated with more severe strokes compared with male sex[104]. As females with AF have higher prevalence of Total Anterior Circulation Stroke indicating proximal vessel occlusion, it is hypothesized that biological differences, such as the smaller diameter of intracranial and extracranial vessels in females compared with males, contribute to in their occlusion[104]. Differences in sex hormones and poorer quality anticoagulation control have also been suggested as causes, though they were not confirmed[104,105].

Female sex is also a strong risk modifier in AF, and the excess risk for women is particularly evident among those with ≥2 non-sex-related stroke risk factors[105].

## Future directions: arterial calcification as a novel risk marker for AF and stroke

Vascular calcification is the deposition of minerals in the intimal and medial layers of the vessel wall secondary to processes such as aging, CKD, diabetes or certain hereditary conditions. It is associated with increased risk of adverse cardiovascular outcomes(80). Multiple mechanisms have been suggested for calcific vasculopathy including: inflammatory (affecting the intimal layer of the vessel; associated atherosclerosis), metabolic (affecting the media; associated with CKD and diabetes), genetic as in Marfan’s syndrome(81). Various studies have looked into arterial calcification involving the intracranial arteries particularly the intracranial internal carotid artery, and the coronary arteries, and their association with adverse cardiovascular events(82)(83)(84)(41).

Calcification of the intracranial internal carotid artery (iICA) was the focus of research as well. It was previously perceived as a proxy for atherosclerosis which tends to affect the intimal layer. The iICA calcification is now rather known to be predominantly found in the medial layer of the artery. While intimal calcification is associated with vessel stenosis, medial calcification results in arterial stiffness, increased pulse pressure and vascular resistance[110,111].

Intimal calcification and/ or medial calcification of the iICA and their severity are independent risk factors for stroke(84). ICA calcification was found to result in 75% of all strokes in middle-aged and elderly white population in the Rotterdam study(41). In addition, severe intracranial artery calcification has also been linked to worse stroke outcomes including recurrence and mortality, as well as certain aetiologies of stroke such as cardio-embolism or large vessel atherosclerosis[112]. Of note, iICA intimal calcification is also an independent risk factor for MI[110].

Coronary artery calcification (CAC) has also been studied. In the MESA cohort, CAC was strongly associated with the 10-year incident risk of atherosclerotic cardiovascular disease (ASCVD) which includes coronary heart disease death, non-fatal MI, fatal and non-fatal stroke[108].

In addition, CAC has also been associated with increased risk for AF[113], a risk that was higher for the younger compared with the older participants in the MESA cohort. The risk of AF also increased with higher levels of CAC progression[113].

In a retrospective case-control trial by Hillerson et al. an incidental finding of coronary artery calcification was also independently associated with increased risk of stroke and death in AF patients[114]. Similar findings were reported by Wang et al.[115]. This may call for further studies in order to incorporate CAC into stroke risk scores in AF patients.

# Considerations on the acute management of ischaemic stroke in patients with AF

## Thrombolytic therapy

Administered within 4.5 hours of symptoms onset, intravenous (IV) alteplase (recombinant tissue plasminogen activator [tPA]) improves the outcomes of ischemic stroke, with time-to-treatment dependent benefit[116]. This proportional benefit did not differ between younger patients and those older than 80 years of age and was evident irrespective of stroke severity[116]. The European Stroke Organisation (ESO) guidelines also recommend the use of IV Tenecteplase (as alternative thrombolytic agent) in patients with large vessel occlusion (LVO) stroke, who are candidates for mechanical thrombectomy (MT) and present within 4.5 hours of stroke onset[117].

Being on OAC is not an absolute contraindication to IV thrombolysis; the ESO guidelines recommend IV tPA for those already on VKAs if INR ≤1.7[118]. However, data for IV thrombolysis in patients who are on DOAC are conflicting.

### Breakthrough stroke while on a Direct Oral Anticoagulant (DOAC) and use of reversal agents to facilitate thrombolysis

Patients on DOACs presenting with acute stroke present a challenge as ways of measuring DOACs activity are limited. A dilemma presents to the treating physician when thrombolysis is indicated in a patient who is already taking a DOAC, as the use of alteplase in patients treated with a DOAC within 48 hours of stroke onset is associated with perceived increased risk of symptomatic intracranial haemorrhage[118].

Several approaches have been suggested to managing patients on DOACs requiring thrombolysis. Major international guidelines [119] state that if a DOAC has been received >48 hours, then IVT can be administered [119]. Use of blood tests (e.g., calibrated anti-Xa-activity for factor Xa inhibitors, thrombin time for dabigatran, or the DOAC blood concentrations) is referred to in some guidelines with limited evidence supporting these recommendations, this is in addition to its cost and limited availability in most settings[120]. Although various studies have suggested cut-off levels for the use of specific anticoagulants assays, these have not been validated except for rivaroxaban (< 20ng/ml)[121].

Use of specific DOACs reversal agents including Andexanet for Apixaban and Rivaroxaban, or Idarucizumab for Dabigatran, can facilitate the use of thrombolysis. Limited data are available in this context. Andexanet can effectively reverse effects of apixaban and rivaroxaban, with its main use being the control of life-threatening or uncontrolled bleeding [122]. In patients presenting with stroke however, a major limitation to its use is that it requires about 2 hours to administer. Considering the 4.5-hour window for thrombolysis, its clinical utility is thus significantly limited. There is also a concern about its potential for causing rebound thrombosis with a rate of 10% at 30 days [122]. Another concern is the increased incidence of thromboembolic events and risk of cardiac events [123]. Based on this evidence, ESO cautions against the use of Andexanet for reversal of apixaban or rivaroxaban in patients eligible for thrombolysis [121].

Idarucizumab on the other hand, can be used to reverse dabigatran used within 48 hours. There is again a fear of its prothrombotic effects particularly in patients with acute stroke. European stroke society, was therefore, unable to recommend for or against its use in patients otherwise eligible for IVT [119]. A recent meta-analysis has suggested that use of reversal agents in patients with acute ischemic stroke while on DOACs is safe, however, more data are required to prove this [124].

The recent international multicenter study by Meinel et al.[125] tried to address many of the above-mentioned concerns. In this study, adults with acute ischemic stroke who were treated with IVT (with or without MT) were included if they ingested a DOAC within the preceding 48 hours (total number was 832). The control group was formed of 32 375 patients with acute ischemic stroke receiving IVT without history of prior anticoagulation treatment (defined as being on DOAC treatment or on VKA with therapeutic INR >1.7). Data on selection strategy within the DOAC group were also gathered: 355 (42.7%) were treated with IVT without measurement of DOAC plasma levels or administration of a reversal agent, 252 (30.3%) received DOAC reversal prior to IVT (idarucizumab was the only agent used in patients taking dabigatran), and 225 (27.0%) had DOAC plasma levels measured. The primary outcome was symptomatic ICH (sICH); defined as any ICH occurring up to 36 hours after IVT, with associated ≥4 point-increase in NIHSS score attributable to radiographically evident haemorrhage. The unadjusted rate of sICH was 2.5% (95% CI, 1.6-3.8) in the DOAC group compared with 4.1% (95% CI, 3.9-4.4) in the control group. Even after adjusting for stroke severity and other predictors of sICH, recent DOAC ingestion was not associated with increased risk of sICH (adjusted odds ratio: 0.57; 95% CI: 0.36-0.92, P: 0.02). There was no statistical difference between the selection strategies[125]. While the study had its limitations, such as the likely selection bias towards patients with a low probability for sICH (when IVT was given without measurement of DOAC plasma levels or use of a reversal agent), it provided new and crucial evidence signalling the safety of IVT in ischemic stroke patients who had recently ingested a DOAC.

## Mechanical thrombectomy for stroke and the impact of AF

Mechanical thrombectomy (MT) is the goal standard for treatment in ischemic stroke with large vessel occlusion (LVO)[126]. It is recommended in addition to best medical management (including IVT, if indicated) [127]. It improves the functional outcome in those presenting within 6 hours of symptoms onset [126]. Careful patient selection using advanced imaging has also allowed more patients to receive MT up to 24 hours of symptoms onset[128][129].

Some data suggest that patients with AF, who received MT for stroke, tend to have worse 90-day outcomes with significantly higher mortality rates and significantly lower rates of functional independence, even in the setting of comparable rates of successful reperfusion to those without AF. This could possibly be attributed to the older age of AF population and the associated co-morbidities seen in this group [130]. The presence of AF itself was not found to affect the good short-term outcome or the short-term and long-term mortality in patients with acute ischemic stroke who were treated with MT[131]. Hence, these findings should not deter MT on patients with AF and concomitant LVO, irrespective of anticoagulant treatment.

## Anticoagulation timing after stroke in AF

The optimal timing for (re-)starting OAC after an acute ischemic stroke in patients with AF has been unclear. The concerns regarding the risk of recurrent stroke in this group must be balanced against the perceived competing risk of secondary haemorrhagic transformation. The current European guidelines suggest considering (re-)initiation of OAC at 1 or 1-3 days after TIA (depending on findings on brain imaging), or at ≥ 3, ≥6-8, or ≥12-14 days after a mild, moderate, or severe ischaemic stroke with no evidence of haemorrhagic transformation, respectively[132]. This approach has also been supported by a study of the data from the National Health Insurance Research Database of more than 12000 AF patients hospitalised for ischaemic stroke in Taiwan[133].

The Early Versus Delayed Non–Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING) trial[134]assessed the noninferiority of early versus late initiation of DOAC after an ischaemic stroke in 34 stroke units in Sweden. Stroke patients were randomised within 72 hours of symptom onset to early (≤4 days) or delayed (5–10 days) DOAC initiation. Early initiation was noninferior to delayed initiation with respect to the primary outcome (a composite of recurrent ischemic stroke, symptomatic ICH, or all-cause death at 90 days). Numerically lower rates of ischemic stroke and death were noted in the early initiation group. No symptomatic ICH was recorded in either of the study groups during 90 days of follow-up. However, the study was underpowered, and while a sample size of 1451 per group was calculated to assess noninferiority with a power of 80% using a significance level of 5%, only 888 patients were included in the final cohort and assigned to each group[134].

The recently published Early versus Late Initiation of Direct Oral Anticoagulants in Post-ischemic Stroke Patients with Atrial Fibrillation (ELAN) trial[135], was an international multicenter trial involving 103 stroke centers in Europe, the Middle East, and Asia. It compared the early (within 48 hours after a minor or moderate stroke or on day 6 or 7 after a major stroke) versus late (day 3 or 4 after a minor stroke, day 6 or 7 after a moderate stroke, or day 12, 13, or 14 after a major stroke) initiation of DOAC in patients with AF. There was no statistically significant difference between the early-treatment group and the later-treatment group in the rates of the primary outcome (a composite of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic ICH, or vascular death within 30 days after randomization). The two groups did not differ either in the risk of recurrent ischemic stroke, ICH or vascular death at 30 and 90 days)[135]. The trial suggested no excess harm with the early use of DOAC after ischemic stroke and may advise an important change in clinical practice and guidelines.

The Optimal Timing of Anticoagulation after Acute Ischemic Stroke (OPTIMAS) trial (ClinicalTrials.gov number, NCT03759938) have opened in multiple centres in the UK since December 2021 and is still ongoing. It looks at assessing the non-inferiority of early versus late initiation of DOAC in patient with AF after an acute ischemic stroke, with a non-inferiority margin of 2 percentage points.

# Mitigating the long-term risk of stroke in AF

## The conundrum of antithrombotic therapy for secondary prevention of stroke in AF patient already on OAC treatment

Despite our best efforts at stroke prevention, patients with AF still have an annual ischemic stroke risk of 1-3% while on effective OAC treatment [136]. In a pooled data analysis of 7 prospective cohort studies, patients with AF developing stroke whilst on OAC were found to have a higher stroke recurrence risk compared to those who were OAC-naïve despite similar CHA2DS2‐Vasc and HAS‐BLED scores[137]. In such cases of breakthrough strokes, the optimal antithrombotic strategy had been uncertain.

In the pooled analysis by Seiffge et al.[137], the final cohort of about 5000 patients were followed up for at least 3 months post ischemic stroke or TIA. Changing the type of OAC after the index event in this cohort was not associated with a decreased risk of further strokes.

More recently, Ip et al*.*[138]studied the antithrombotic strategies for patients with AF already on DOAC at the time of an ischemic strokes. The potential strategies included: continuing on the same DOAC (DOAC-same), DOAC-to-warfarin switch, DOAC-to-DOAC switch (DOAC-switch), or addition of antiplatelet agents. Bonaventure Ip et al.compared the clinical outcomes of patients in each of those 4 groups over a median follow up period of 16.5months. The strategy of continuing the same DOAC was associated with the lowest annual risk for recurrent stroke (8.7%). DOAC-switch and the DOAC to warfarin switch strategies were associated with increased risk of recurrent stroke compared to the DOAC-same strategy (adjusted hazard ration[aHR]1.96, 95% CI 1.29–3.02, p = 0.002, and aHR 1.62, 95% CI 1.25–2.11, p < 0.001 respectively). Adjunctive antiplatelet treatment among the DOAC-same group did not reduce the risk of recurrent ischemic stroke (aHR 1.28, 95% CI 0.88–1.84, p = 0.188), ICH (aHR 1.20, 95% CI 0.54–2.68, p = 0.654), or death (aHR 1.09, 95% CI 0.84–1.41, p = 0.512). On the other hand, the risk of ICH and death was not significantly different between the groups[138].

## Non-medical options for prevention of stroke in AF patients

While oral anticoagulation is the main pillar of secondary prevention post stroke in AF patients[52,77,79,139,140], left atrial appendage occlusion or exclusion might provide a reasonable alternative or adjunctive therapy in certain cases.

### Left atrial appendage occlusion devices

In non-valvular AF, an embolic stroke is believed to be secondary to a thrombus formed in the left atrial appendage (LAA)[141]. Percutaneous LAA occlusion with Watchman Left Atrial Appendage System was investigated in the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) study, and was found non-inferior to warfarin therapy in prevention of stroke in AF patients, though it was associated with higher rate of adverse safety events in the intervention group mainly secondary to periprocedural complications[141,142]. It is also important to note that the non-inferiority was mainly driven by reduction in rates of haemorrhagic strokes and not ischemic strokes.

Similar outcome was seen in the Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial[143]. In this trial, non-inferiority was only achieved after isolating periprocedural events, and LAA occlusion was noninferior to warfarin for prevention of ischemic stroke or systemic embolism >7 days post-procedure. Neither PROTECT AF nor PREVAIL compared the safety and efficacy of LAA occlusion to NOAC or in patients who have contraindication to oral anticoagulants (OACs).

Those with contraindications to OAC were assessed in the ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)[144]. Comparing the outcomes rates in this trial’s intervention group to the annual stroke/TIA risk using CHADS2 score, showed that the LAA closure with the Watchman device can provide a reasonable alternative in patients at high risk for stroke but with contraindications to OACs.

OAC vs LAA closure was studied in the PRAGUE-17 trial (using Amulet or the Watchman device), and OACs were found non-inferior to LAA occlusion in the prevention of major AF-related cardiovascular, neurological, and bleeding events in patients known to have high bleeding and stroke risk[145], **Table 1** summarizes the trials studying percutaneous LAA occlusion.

In the real-world data, the frequency of in-hospital adverse outcomes associated with percutaneous LAA closure is slightly higher at 24.3% than in clinical trials[146]. Currently, the ESC guidelines suggest a class IIb indication for consideration of LAA occlusion in AF patients at risk of stroke but with contraindication for long-term OAC[147].

### Surgical LAA occlusion or exclusion surgery

The Left Atrial Appendage Occlusion Study II (LAAOS II)[148] was a cross-sectional study and a pilot trial that included 51 AF patients undergoing cardiac surgery. The primary end point (a composite of death, MI, stroke, non-cerebral systemic emboli, or major bleeding) occurred in 15.4% in the occlusion arm and 20.0% in the no-occlusion (relative risk [RR], 0.71; 95% confidence interval [CI], 0.19-2.66; *P* = 0.61). The predominant component of the composite was stroke, with 1 in the occlusion arm and 3 in the no-occlusion arm. Nevertheless, the study confirmed feasibility of the procedure.

LAA exclusion using a double ligation technique (with both a polydioxanone (PDS) II endosnare and a running 4-0 Prolene pledgeted suture) was studied and it yielded positive results among 808 trial participants[149]. The technique was associated with lower rates of in-hospital and 30-day mortality without an increase in perioperative complications. There was a trend towards less post-operative AF (19.4% vs 22.9%, P = 0.07).

The LAAOS III trial[150] is the only randomised controlled trial assessing the efficacy of surgical LAAO in patients undergoing cardiac surgery. All participants had AF with CHA2DS2-VASc score of 2 or above. They all received anticoagulation after surgery. Concomitant occlusion of the LAA during cardiac surgery was more effective than standard therapy alone in reducing the risk of ischaemic stroke in these patients. On the other hand, the procedure was found safe and did not increase the risk of bleeding or death. The current ESC guidelines suggest class IIb indication for surgical LAA occlusion or exclusion for stroke prevention in AF patients undergoing cardiac surgery[147].

## The Atrial Fibrillation Better Care (ABC) pathway

The ABC pathway was suggested in 2017 for a streamlined management of AF, and was subsequently adopted in the European Society of Cardiology (ESC) guidelines[147,151]. ‘A’ stands for avoid stroke, ‘B’ is for better symptom management, and ‘C’ is for cardiovascular and comorbidity risk reduction[151]. Such integrated care approach was introduced to allow a structured management for AF that can be applied by the general practitioner or any hospital-based specialist (even the non-cardiologists)[152]. It also facilitates discussion and patient engagement on the principles of AF care (“easy as ABC…”)[152].

ABC pathway in AF patients has been supported by posthoc analysis of trial data as well as prospective randomised controlled trial data[153–155].

### Integrated care post-stroke in relation to incident cardiovascular events, including AF

Stroke-heart syndrome is a term used to describe the cardiac manifestations occurring as a consequence of brain ischaemia[156]. New onset major adverse cardiovascular events (MACE), including acute coronary syndrome, heart failure, and arrhythmias has been reported at a rate of up to 20% in the acute phase of ischaemic stroke[156]. It is suggested that they have the same underlying autonomic and inflammatory mechanisms as stroke[157]. In a retrospective cohort study of 365 383 patients with stroke, 11.1% developed acute coronary syndrome, 8.8% AF/flutter, 6.4% heart failure, 1.2% severe ventricular arrythmia, and 0.1% Takotsubo syndrome within 4 weeks of the index stroke. Those with stroke and newly diagnosed cardiovascular complications had worse prognosis and >50% prevalence of recurrent stroke at 5 years[157]. The risk of subsequent cardiovascular events is similar between incident haemorrhagic and ischemic stroke[158].

A post-stroke ABC pathway has been proposed to provide a more holistic approach to integrated stroke care. Its main pillars are: “A” for appropriate antithrombotic therapy, “B” for better functional and psychological status, and “C” for cardiovascular risk factors and comorbidity optimization (including lifestyle changes)[152]. The European Society of Cardiology Council on Stroke issued a consensus statement in support of this approach[159].

In a systematic review and metanalysis assessing the impact of ‘Atrial Fibrillation Better Care’ pathway on the clinical outcomes of AF patients, patients treated according to the ABC pathway had a lower risk of all-cause death (odd ration (OR): 0.42; 95% CI: 0.31–0.56), cardiovascular death (OR: 0.37; 95% CI: 0.23–0.58), stroke (OR: 0.55; 95% CI: 0.37–0.82) and major bleeding (OR: 0.69; 95% CI: 0.51–0.94)[160].

## Management of large vessel disease and AF

Existing data suggest that the presence of asymptomatic carotid artery stenosis increases the risk of stroke by 50%[161]. However, the risk gradient between the severity of asymptomatic lesions causing 50% luminal narrowing or more and stroke is less clear[162]. In these patients, triple medical therapy with anti-thrombotic, anti-hypertensive and LDL cholesterol-lowering agents decreases the risk of stroke, myocardial infarction and death[162]. In patients with AF and coexisting carotid artery stenosis, there is no evidence that adding aspirin to OAC reduces the risk of recurrent stroke[162,163].

# Detection of AF after stroke

## Risk scores for predicting AF in patients with stroke

AF-related strokes tend to be associated with worse functional deficit, poor survival and higher recurrence rate within 12 months compared to strokes in non-AF individuals[164]. Hence, early detection of AF in stroke patients is vital for secondary prevention.

In a large prospective multicenter study by Grond et al.[52] stroke patients with otherwise undiagnosed AF (silent AF) were of older age and less functional disability before their index stroke, but sustained a more severe neurological deficit. Radiologically, there was no clear preference for a specific vascular territory involvement in undiagnosed AF patients compared to those in sinus rhythm, and imaging features suggestive of cardioembolic mechanism (i.e., multiple infarctions) were not more common in the former group either[52].

Various studies have looked into predicting AF in patients who have had an acute stroke or TIA (**Table 2**)[165–175]. Predicting AF in such high-risk groups can identify the subset of patients who need more extensive investigations and guide the screening strategy for AF. The generated scores or models have not been formally incorporated into clinical guidelines as yet, although position papers or consensus documents have advocated simple scores such as the C2HEST score.

In the Score for the Targeting of Atrial Fibrillation (STAF) study[165], 4 variables were used to calculate the STAF score of 0-8. These were: age >62 years (2 points); the National Institutes of Health Stroke Scale (NIHSS) ≥8 (1 point); left atrial dilatation (2 points); absence of symptomatic intra or extra-cranial stenosis ≥50%, or clinico-radiological lacunar syndrome (3 points). A total score of 5 or more had 89% sensitivity and 88% specificity in detecting AF. In this trial, TIA patients were excluded.

The LADS system on the other hand was developed to identify both stroke and TIA patients who may have AF[166]. This includes: Left atrial diameter (0–2 points), Age (0–2 points), Diagnosis of stroke (0–1 point), and Smoking status currently (0–1 point). A score of 4 or greater had a sensitivity of 85.5% and a specificity of 53.1%.

The C2HEST score was originally developed and validated to assess the individual risk of developing AF in the Asian population without structural heart disease[171].Variables included in this score were: (coronary artery disease or chronic obstructive pulmonary disease [1 point each]; hypertension [1 point]; elderly [age ≥75 years, 2 points]; systolic HF [2 points]; thyroid disease [hyperthyroidism, 1 point]), total points of 0-8. The score was then tested in a post stroke white European population in a French nationwide study by Li et al.(71). The annual incidence rates of AF in this study were 3.19% in the low-risk group (0 or 1 point), 7.15% in the medium-risk group (2 or 3 points), and 14.64% in the high-risk group (≥4 points).

Another scoring system for identifying those at risk of developing AF among patients with cryptogenic stroke or TIA is the HAVOC score[169] (**h**ypertension [2 points], **a**ge [2 points], **v**alvular heart disease [2 points], peripheral **v**ascular disease [1 point], **o**besity (body mass index (BMI) of >30) [1 point], **c**ongestive heart failure [4 points], and **c**oronary artery disease [2 points]); a total of 0-14 points. 3 risk categories were developed: low risk (scores 0–4), medium risk (5–9), and high risk (10–14), and AF rates were 2.5%, 11.8%, and 24.9% respectively, and AF rates >30 days after the stroke in the validation cohort were 2.6%, 11.1%, and 20.3% respectively. In an external assessment of the performance of HAVOC score in predicting incident AF in patients with embolic stroke of undetermined source (ESUS) (72), low-risk HAVOC score had a specificity of 88.7% in identifying patients without incident AF, a negative predictive value of 85.1%, and an accuracy of 78.0%.

In the CHARGE-AF, variables including age, race, height, weight, systolic and diastolic blood pressure, current smoking, use of antihypertensive medication, diabetes, and history of myocardial infarction and heart failure were used to create and validate a 5 year predictive model of AF in 5 community-based US and European cohorts (the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular Health Study (CHS), the Framingham Heart Study (FHS), the Rotterdam Study (RS), and the Age Gene/Environment Susceptibility‐Reykjavik (AGES) Study)[172]. Even though the model was tested in community-based cohorts (AGES and RS) rather than in post-stroke patients, it proved good discrimination (C‐statistic, 0.765; 95% CI, 0.748 to 0.781). In a report comparing the CHARGE-AF versus CHA2DS2-VASc risk score, the CHARGE-AF had a C-statistic of 0.757 (95% CI, 0.741–0.772) as opposed to C- statistics of CHA2DS2-VASc score of 0.712 (95% CI, 0.693–0.731)[173]. Reports from the multi-ethnic study of atherosclerosis (MESA) studies also suggest that the CHARGE-AF risk score is superior to the CHA2DS2-VASc risk score in the prediction of incident AF in community-based cohorts[174].

Predictors of newly diagnosed AF (NDAF) in cryptogenic stroke patients were also studied by Bugnicourt et al.[175], who developed a score including the following variables: age ≥72 years (2 points), history of coronary artery disease (1 point) or stroke (1 point), and left atrial area ≥16 cm2 (2 points); a total score ranging from 0 to 6. A score of 0 or 1 was highly predictive of the absence of NDAF during the one-year follow-up period.

In a systematic review by Kishore et al.[176] the performance of most of the above-mentioned scores, and others, was assessed. Such scores tend to have a high negative predictive value, however, no score performed consistently better than another, and their usefulness in decision making remains uncertain[176].

Randomised controlled trials assessing the risks and benefits of AF screening as a public health strategy to prevent stroke may have signalled reductions in stroke or systemic embolism with screening, but were statistically nonsignificant[177]. This is because of the inherent challenges of screening studies and the need for a very large sample size. Hence, they are often statistically underpowered[177]. Therefore, a systematic review and a metanalysis is important to achieve the sample size and power needed to answer such question. A systematic review and a metanalysis is currently underway by McIntyre et al. to address this area of interest[177].

## Improving the detection rate of AF after stroke

As AF can be paroxysmal, its detection can be challenging but remains of paramount importance as it can guide change in management. Detection of AF in post-stroke patients can instruct initiation of anticoagulation therapy proved to reduce risk of thrombo-embolism in AF[178]. In the study by Elijovich et al., rhythm monitoring with a 30-day event recorder changed the management of one fifth of patients with otherwise cryptogenic stroke due to the detection of intermittent AF on those monitors that had not been picked up on 12-lead electrocardiogram (ECG) or during a period of telemetry during their hospital stay[179]. New AF detection rate from a 12-lead ECG after an ischemic stroke or transient ischemic attack (TIA) is estimated to be about 2-5%, while the detection rate from a 24-hour monitor is about 2-6%[180]. Detection rates are noted to increase by 2% to 4% with each additional 24 hours of monitoring as reported in the meta-analysis by Kishore et al.[180].

Several studies have assessed the optimum duration of rhythm monitoring post-stroke. In a prospective multicenter cohort study conducted in Germany, extending the period of Holter ECG monitoring in stroke survivors to 72 hours almost doubled the detection rate of AF[181]. The AF detection rate in patients with otherwise presumed cryptogenic stroke was even higher at 23% with the use of Mobile Cardiac Outpatient Telemetry (MCOT) system. Eighty-five percent of those detected AF episodes were short and <30 second long. The overall higher detection rate in this study was attributed to longer monitoring period (up to 21 days after stroke), patient selection and inclusion of all new onset AF[182].

Insertable cardiac monitors (ICM), such as Reveal XT (Medtronic Inc, Minneapolis), which were originally designed to investigate syncope were subsequently refined to incorporate algorithms detecting AF[183]. In the study by Ritter et al., ICM had a 17% AF detection rate as opposed to 1.7% for 7-day Holter monitoring[183]. Similarly, Israel et al. studied the use of implantable loop recorder (ILR) in patients labelled with embolic stroke of unknown source (ESUS), and AF was detected in about 25% of those patients within one year of ILR monitoring and daily remote interrogation[184].

In the Cryptogenic Stroke and Underlying AF (CRYSTAL-AF) trial[185], ECG monitoring with ICM was found superior to conventional follow up in detection of AF after cryptogenic stroke. AF detection rate was significantly higher in the ICM group compared to the control group at 6 months and 12 months (8.9% vs 1.4%, and 12.4% vs 2% respectively).

### Future directions in AF detection using wearable devices and artificial intelligence (AI)

With advancing technology, new means of detecting AF have come to light. As low detection rate and non-adherence continue to be major obstacles in the management approach to suspected AF, use of mobile health devices may help and facilitate continuous home monitoring[186]. In the Apple Heart Study[187], participants who self-reported not having AF were enrolled. They gave consent via their smart phone (Apple iPhone) application (App). Those who received an “irregular heart pulse” notification via the smart watch were mailed an ECG patch from telemedicine. About half a million of participants were enrolled, only 0.52% received an irregular pulse notification. The positive predictive value for AF was 84% (95% CI, 76 to 92%).

The use of smart device–based photoplethysmography (PPG) technology in detection of AF was also studied in a large population in China with the use of a wristband (Honor Band 4) or wristwatch (Huawei Watch GT, Honor Watch, Huawei Technologies Co., Ltd., Shenzhen, China)[186]. When a “possible AF” alert is sent, further assessment is carried out by health providers among the MAFA (mobile AF App) Telecare center and network hospitals in order to confirm AF with clinical evaluation, ECG, or 24-hour Holter monitoring [186]. Out of 186,956 participants, 0.2% had a suspected AF notification, and 87% of those had AF confirmed by doctors. 95.1% then entered the MAFA integrated care program based on the Atrial fibrillation Better Care (ABC) pathway. The positive predictive value of PPG signals was 91.6% (95% CI: 91.5% to 91.8%). The study showed the feasibility of PPG-based smart devices as a screening tool for AF patients.

The Liverpool-Huawei Stroke Study (Identifier: <https://doi.org/10.1186/ISRCTN30693819>) is actively recruiting patients with stroke to evaluate the feasibility and clinical effectiveness of using the Huawei smart band in detection of incident and prevalent AF[188].

Other technologies investing in the use of artificial intelligence (AI) methods such as deep learning (DL) have been explored. Models have been proposed to predict the likelihood of a person having underlying undiagnosed AF from an ‘apparently normal’ ECG without any additional information[189]. In one study, the ability of AI-ECG model to predict AF in ESUS patients was measured against the results of prolonged ambulatory cardiac rhythm monitoring[190]. While the AF probability by AI-ECG was not associated with ESUS, the probability of AF by AI-ECG in ESUS patients was associated with a higher probability of AF detection by ambulatory monitoring (P = 0.004)[190].

In a study by Khurshid et al.[191], a convolutional neural network was trained to draw the 5-year incident AF risk using 12-lead ECGs in patients receiving longitudinal primary care in a state in the USA. The overall performance of the model was tested in the UK Biobank data and it showed a comparable performance to the CHARGE-AF risk score[191]. This suggested the potential comparable predictive utility of these innovative tools to clinical risk factor models, though more testing and clinical trials are needed in the future before any conclusions are drawn and generalized.

# Conclusions

Reducing the risk of recurrent stroke is a primary goal in the therapeutic journey after a stroke, identifying covert AF is crucial to advise on the need for anticoagulation treatment. Several risk scores have been developed to predict AF after stroke, thereby identifying individuals where prolonged rhythm monitoring periods might be necessary. However, their applicability in clinical practice remains uncertain, and they are yet to be implemented in any clinical guidelines.

Breakthrough strokes in patients with AF already on DOACs have presented a clinical conundrum. It has recently emerged that the early (re-)initiation of OAC in for secondary prevention in patients with AF is not associated with increased risk of recurrent ischemic stroke or ICH.

Advancing technologies such as the use of smart wearables have been studied with promising results, but their use and clinical effectiveness in the high-risk post stroke population is yet to be validated. Novel predictors of AF and markers of stroke risk in AF such as arterial calcification of the coronary and the intracranial arteries have been explored but not yet incorporated into any clinical risk models.

With advancing technology, innovative algorithms leveraging AI to interpret ECGs have been developed. However, more work and large-scale testing is still required. Appropriate validation and testing in large randomized trials are also needed before these tools can be widely used and applied in clinical practice.

# Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

# Author Contributions

SE drafted the initial manuscript. GYHL and AHAR supervised the project. All co-authors reviewed the manuscript, made critical revision for key intellectual content and approved the final version.

# Funding

No funds, grants, or other support was received.

# References

[1] Murtagh B, Smalling RW. Cardioembolic stroke. Curr Atheroscler Rep. 2006;8:310–316.

[2] Marini C, De Santis F, Sacco S, et al. Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke. Stroke [Internet]. 2005 [cited 2022 Jul 15];36:1115–1119. Available from: https://www.ahajournals.org/doi/abs/10.1161/01.STR.0000166053.83476.4a.

[3] Rogers PA, Bernard ML, Madias C, et al. Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation. Curr Probl Cardiol. 2018;43:241–283.

[4] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The framingham study. Stroke [Internet]. 1991 [cited 2022 Jul 20];22:983–988. Available from: http://ahajournals.org.

[5] Healey JS, Connolly SJ, Gold MR, et al. Subclinical Atrial Fibrillation and the Risk of Stroke A bs tr ac t. 2012.

[6] Glotzer T V, Hellkamp AS, Zimmerman J, et al. Atrial High Rate Episodes Detected by Pacemaker Diagnostics Predict Death and Stroke Report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). 2003; Available from: http://www.circulationaha.org.

[7] Kirchhof P, Toennis T, Goette A, et al. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. New England Journal of Medicine. 2023;

[8] Kamel H, Okin PM, Elkind MSV, et al. Atrial Fibrillation and Mechanisms of Stroke. Stroke [Internet]. 2016 [cited 2023 Feb 17];47:895–900. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.115.012004.

[9] Vinding NE, Kristensen SL, Rørth R, et al. Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation. J Am Heart Assoc. 2022;11.

[10] Tu HTH, Campbell BCV, Christensen S, et al. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis [Internet]. 2010 [cited 2023 Jan 4];30:389–395. Available from: https://pubmed.ncbi.nlm.nih.gov/20693794/.

[11] Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. International Journal of Stroke. 2021;16:217–221.

[12] Kavousi M. Differences in Epidemiology and Risk Factors for Atrial Fibrillation Between Women and Men. Front Cardiovasc Med. Frontiers Media S.A.; 2020.

[13] Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. Available from: http://dx.doi.org/10.1136/bmj.i4482.

[14] Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of Atrial Fibrillation in the 21st Century. Circ Res [Internet]. 2020 [cited 2022 Mar 9];127:4–20. Available from: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.316340.

[15] Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. Circulation. 2014;129:837–847.

[16] Borzecki AM, Keith Bridgers D, Liebschutz JM, et al. Racial Differences in the Prevalence of Atrial Fibrillation among Males. J Natl Med Assoc. 2008;100:237–246.

[17] Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. Lippincott Williams and Wilkins; 2020. p. 4–20.

[18] Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111–117.

[19] Marcus GM, Alonso A, Peralta CA, et al. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation. 2010;122:2009–2015.

[20] Fried LP, Borhani NO, Enright P, et al. The cardiovascular health study: Design and rationale. Ann Epidemiol. 1991;1:263–276.

[21] Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: The framingham heart study. Circulation. 2004;110:1042–1046.

[22] Wang L, Ze F, Li J, et al. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017 Arrhythmias and sudden death. Heart [Internet]. 2021 [cited 2023 Aug 30];107:881–887. Available from: http://dx.doi.org/10.1136/heartjnl-2020-317656.

[23] Ohlrogge AH, Brederecke J, Schnabel RB. Global Burden of Atrial Fibrillation and Flutter by National Income: Results From the Global Burden of Disease 2019 Database. J Am Heart Assoc [Internet]. 2023; Available from: https://www.ahajournals.org/doi/10.1161/JAHA.123.030438.

[24] Essa H, Hill AM, Lip GYH. Atrial Fibrillation and Stroke. Card Electrophysiol Clin. W.B. Saunders; 2021. p. 243–255.

[25] Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart. 2004;90:286–292.

[26] Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes [Internet]. 2022 [cited 2023 Aug 30];8:187–194. Available from: https://dx.doi.org/10.1093/ehjqcco/qcaa093.

[27] Chung S-C, Sofat R, Acosta-Mena D, et al. Atrial fibrillation epidemiology, disparity and healthcare contacts: a population-wide study of 5.6 million individuals. The Lancet Regional Health - Europe. 2021;7:100157.

[28] Tsai CF, Thomas B, Sudlow CLM. Epidemiology of stroke and its subtypes in Chinese vs white populations. Neurology. 2013;81:264–272.

[29] Saini V, Guada L, Yavagal DR. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions. Neurology. 2021;97:S6–S16.

[30] Bos D, Portegies MLP, Van Der Lugt A, et al. Intracranial Carotid Artery Atherosclerosis and the Risk of Stroke in Whites: The Rotterdam Study. JAMA Neurol [Internet]. 2014 [cited 2022 Jul 26];71:405–411. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/1828513.

[31] Goldstein LB. Introduction for focused updates in cerebrovascular disease. Stroke [Internet]. 2020 [cited 2023 Feb 5];708–710. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.119.024159.

[32] Amarenco P, Bogousslavsky J, Caplan LR, et al. Classification of Stroke Subtypes. Cerebrovascular Diseases [Internet]. 2009 [cited 2023 Feb 5];27:493–501. Available from: https://www.karger.com/Article/FullText/210432.

[33] Ay H, Furie KL, Singhal A, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol [Internet]. 2005 [cited 2023 Feb 14];58:688–697. Available from: https://onlinelibrary-wiley-com.liverpool.idm.oclc.org/doi/full/10.1002/ana.20617.

[34] Mohr JP, Caplan LR, Melski JW, et al. The Harvard Cooperative Stroke Registry: A prospective registry. Neurology. 1978;28:754–762.

[35] Sacco RL, Ellenberg JH, Mohr JP, et al. Stroke Data Bank. Ann Neurol [Internet]. 1989 [cited 2023 Feb 12];25:382–390. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ana.410250410.

[36] Adams HP, Bendixen BH, Kappelle ; L Jaap, et al. Classification of subtype of acute ischemic stroke definitions for use in a multicenter clinical trial. Stroke [Internet]. 1993 [cited 2023 Feb 15];24:35–41. Available from: http://ahajournals.org.

[37] Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: The causative classification of stroke system. Stroke. 2007;38:2979–2984.

[38] Bogiatzi C, Wannarong T, McLeod AI, et al. SPARKLE (Subtypes of Ischaemic Stroke Classification System), Incorporating Measurement of Carotid Plaque Burden: A New Validated Tool for the Classification of Ischemic Stroke Subtypes. Neuroepidemiology [Internet]. 2014 [cited 2023 Feb 5];42:243–251. Available from: https://www.karger.com/Article/FullText/362417.

[39] Iemolo F, Martiniuk A, Steinman DA, et al. Sex Differences in Carotid Plaque and Stenosis. Stroke [Internet]. 2004 [cited 2023 Feb 16];35:477–481. Available from: http://ahajournals.org.

[40] Spence JD, Eliasziw M, DiCicco M, et al. Carotid Plaque Area. Stroke [Internet]. 2002 [cited 2023 Feb 16];33:2916–2922. Available from: https://www.ahajournals.org/doi/abs/10.1161/01.str.0000042207.16156.b9.

[41] Chen PS, Chen LS, Fishbein MC, et al. Role of the Autonomic Nervous System in Atrial Fibrillation. Circ Res [Internet]. 2014 [cited 2023 Feb 17];114:1500–1515. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.114.303772.

[42] Scheitz JF, Nolte CH, Doehner W, et al. Stroke–heart syndrome: clinical presentation and underlying mechanisms. Lancet Neurol. 2018;17:1109–1120.

[43] Sposato LA, Chaturvedi S, Hsieh CY, et al. Atrial Fibrillation Detected after Stroke and Transient Ischemic Attack: A Novel Clinical Concept Challenging Current Views. Stroke. 2022;29:E94–E103.

[44] Cerasuolo JO, Cipriano LE, Sposato LA. The complexity of atrial fibrillation newly diagnosed after ischemic stroke and transient ischemic attack: Advances and uncertainties. Curr Opin Neurol. 2017;30:28–37.

[45] Wang Y, Qian Y, Smerin D, et al. Newly Detected Atrial Fibrillation after Acute Stroke: A Narrative Review of Causes and Implications. Cardiology (Switzerland). 2019;144:112–121.

[46] Sposato LA, Cerasuolo JO, Cipriano LE, et al. Atrial fibrillation detected after stroke is related to a low risk of ischemic stroke recurrence. Neurology. 2018;90:e924–e931.

[47] Alvarado-Bolaños A, Ayan D, Khaw A V., et al. Differences in Stroke Recurrence Risk Between Atrial Fibrillation Detected on ECG and 14-Day Cardiac Monitoring. Stroke [Internet]. 2023 [cited 2023 Aug 30];54:2022–2030. Available from: https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.123.043672.

[48] Sörös P, Hachinski V. Cardiovascular and neurological causes of sudden death after ischaemic stroke. Lancet Neurol. 2012.

[49] Palareti G, Legnani C, Cosmi B, et al. Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study. Int J Lab Hematol. 2016;38:42–49.

[50] Abboud H, Berroir S, Labreuche J, et al. Insular involvement in brain infarction increases risk for cardiac arrhythmia and death. Ann Neurol. 2006;59:691–699.

[51] Sposato LA, Hilz MJ, Aspberg S, et al. Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;76:2768–2785.

[52] Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour holter ecg in patients with ischemic stroke: A prospective multicenter cohort study. Stroke. 2013;44:3357–3364.

[53] Kamel H, Okin PM, Elkind MSV, et al. Atrial Fibrillation and Mechanisms of Stroke. Stroke [Internet]. 2016 [cited 2023 Jan 5];47:895–900. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.115.012004.

[54] Chao TF, Liu CJ, Chen SJ, et al. Atrial fibrillation and the risk of ischemic stroke: Does it still matter in patients with a CHA2DS2-VASc score of 0 or 1? Stroke [Internet]. 2012 [cited 2023 Jan 8];43:2551–2555. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.112.667865.

[55] Investigators TAFFI of RM (AFFIRM). A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. https://doi.org/101056/NEJMoa021328 [Internet]. 2002 [cited 2022 Jul 22];347:1825–1833. Available from: https://www.nejm.org/doi/10.1056/NEJMoa021328.

[56] Al-Khatib SM, LaPointe NMA, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review. Ann Intern Med. 2014;160:760–773.

[57] Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine [Internet]. 2020 [cited 2023 Jun 2];383:1305–1316. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2019422.

[58] Kamel H, Healey JS. Cardioembolic Stroke. Circ Res [Internet]. 2017 [cited 2023 Feb 17];120:514–526. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.116.308407.

[59] Lodder J, Bamford JM, Sandercock PAG, et al. Are hypertension or cardiac embolism likely causes of lacunar infarction? Stroke [Internet]. 1990 [cited 2023 Jan 8];21:375–381. Available from: http://ahajournals.org.

[60] She R, Yan Z, Hao Y, et al. Comorbidity in patients with first-ever ischemic stroke: Disease patterns and their associations with cognitive and physical function. Front Aging Neurosci. 2022;14:1051.

[61] Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of Ischemic Stroke Subtypes According to TOAST Criteria Incidence, Recurrence, and Long-Term Survival in Ischemic Stroke Subtypes: A Population-Based Study. 2001 [cited 2023 Feb 17]; Available from: http://ahajournals.org.

[62] Arboix A. Early differentiation of cardioembolic from atherothrombotic cerebral infarction: A multivariate analysis. Eur J Neurol. 1999;6:677–683.

[63] Timsit SG, Sacco RL, Mohr JP, et al. Early clinical differentiation of cerebral infarction from severe atherosclerotic stenosis and cardioembolism. Stroke [Internet]. 1992 [cited 2023 Feb 18];23:486–491. Available from: http://ahajournals.org.

[64] Saver JL. CLINICAL PRACTICE. Cryptogenic Stroke. N Engl J Med [Internet]. 2016;374:2065–2074. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27223148.

[65] Immediate anticoagulation of embolic stroke: A randomized trial. Cerebral embolism study group. Stroke [Internet]. 1983 [cited 2023 Feb 17];14:668–676. Available from: http://ahajournals.org.

[66] Yaghi S, Elkind MSV. Cryptogenic stroke: A diagnostic challenge. Neurol Clin Pract. 2014;4:386–393.

[67] Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: The case for a new clinical construct. Lancet Neurol. 2014;13:429–438.

[68] Hart RG, Catanese L, Perera KS, et al. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017;48:867–872.

[69] Ntaios G. Embolic Stroke of Undetermined Source: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;75:333–340.

[70] Wachter R, Gröschel K, Gelbrich G, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AFRANDOMISED): an open-label randomised controlled trial. Lancet Neurol. 2017;16:282–290.

[71] Mojadidi MK, Zaman MO, Elgendy IY, et al. Cryptogenic Stroke and Patent Foramen Ovale. J Am Coll Cardiol. 2018;71:1035–1043.

[72] Collado FMS, Poulin MF, Murphy JJ, et al. Patent Foramen Ovale Closure for Stroke Prevention and Other Disorders. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease [Internet]. 2018 [cited 2022 Dec 4];7. Available from: /pmc/articles/PMC6220531/.

[73] Tobis JM, Elgendy AY, Saver JL, et al. Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale–Associated Stroke. JAMA Neurol [Internet]. 2020 [cited 2022 Dec 7];77:878–886. Available from: https://jamanetwork-com.liverpool.idm.oclc.org/journals/jamaneurology/fullarticle/2763602.

[74] Turc G, Calvet D, Guérin P, et al. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease [Internet]. 2018 [cited 2022 Dec 7];7. Available from: /pmc/articles/PMC6220551/.

[75] Strambo D, Sirimarco G, Nannoni S, et al. Embolic Stroke of Undetermined Source and Patent Foramen Ovale: Risk of Paradoxical Embolism Score Validation and Atrial Fibrillation Prediction. Stroke [Internet]. 2021 [cited 2023 Feb 19];1643–1652. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.120.032453.

[76] Heijman J, Voigt N, Nattel S, et al. Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance, and Progression. Circ Res [Internet]. 2014 [cited 2023 Feb 20];114:1483–1499. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCRESAHA.114.302226.

[77] Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J [Internet]. 2015 [cited 2022 Jul 21];36:281–288. Available from: https://academic.oup.com/eurheartj/article/36/5/281/440197.

[78] Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Available from: https://academic.oup.com/eurheartj/article/34/31/2464/454882.

[79] Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000;35:183–187.

[80] Arsava EM, Bas DF, Atalar E, et al. Ischemic stroke phenotype in patients with nonsustained atrial fibrillation. Stroke [Internet]. 2015 [cited 2022 Jul 21];46:634–640. Available from: www.fmrib.ox.ac.uk/fsl].

[81] Botto GL, Padeletti L, Santini M, et al. Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events. J Cardiovasc Electrophysiol. 2009;20:241–248.

[82] Capucci A, Santini M, Padeletti L, et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol. 2005;46:1913–1920.

[83] Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. 2004 [cited 2022 Jul 22]; Available from: http://www.circulationaha.org.

[84] Roy D, Talajic M, Nattel S, et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. https://doi.org/101056/NEJMoa0708789 [Internet]. 2008 [cited 2022 Jul 22];358:2667–2677. Available from: https://www.nejm.org/doi/10.1056/NEJMoa0708789.

[85] Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. New England Journal of Medicine [Internet]. 2016 [cited 2022 Jul 22];374:1911–1921. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1602002.

[86] Sabelle I, Agens IEH, Osker AAB, et al. A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial Fibrillation. https://doi.org/101056/NEJMoa021375 [Internet]. 2002 [cited 2022 Jul 22];347:1834–1840. Available from: https://www.nejm.org/doi/10.1056/NEJMoa021375.

[87] Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690–1696.

[88] Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine. 2020;383:1305–1316.

[89] Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure. Circulation. 2021;845–858.

[90] Rillig A, Borof K, Breithardt G, et al. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation. 2022;146:836–847.

[91] Goette A, Borof K, Breithardt G, et al. Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy. J Am Coll Cardiol. 2022;80:283–295.

[92] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498.

[93] Willems S, Borof K, Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: The EAST-AFNET 4 trial. Eur Heart J. 2022;43:1219–1230.

[94] Van Gelder IC, Ekrami NK, Borof K, et al. Sex Differences in Early Rhythm Control of Atrial Fibrillation in the EAST-AFNET 4 Trial. J Am Coll Cardiol. 2023;81:845–847.

[95] Jensen M, Suling A, Metzner A, et al. Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurol. 2023;22:45–54.

[96] Kany S, Al-taie C, Roselli C, et al. Association of genetic risk and outcomes in patients with atrial fibrillation : interactions with early rhythm control in the EAST-AFNET4 trial. 2023;1–12.

[97] Yu GI, Kim D, Sung JH, et al. Impact of frailty on early rhythm control outcomes in older adults with atrial fibrillation: A nationwide cohort study. Front Cardiovasc Med. 2023;9.

[98] Kang DS, Kim D, Jang E, et al. Sex Difference in Effectiveness of Early Rhythm- over Rate-Control in Patients with Atrial Fibrillation. J Clin Med. 2022;11.

[99] Kany S, Cardoso VR, Bravo L, et al. Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank. Heart. 2022;108:1873–1880.

[100] Proietti M, Vitolo M, Harrison SL, et al. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clinical Research in Cardiology. 2022;111:70–84.

[101] Dickow J, Kirchhof P, Van Houten HK, et al. Generalizability of the EAST-AFNET 4 Trial: Assessing Outcomes of Early RhythmControl Therapy in Patients With Atrial Fibrillation. J Am Heart Assoc. 2022;11.

[102] Zhu W, Wu Z, Dong Y, et al. Effectiveness of early rhythm control in improving clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. BMC Med. 2022;20.

[103] Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation [Internet]. 1998 [cited 2022 Jul 20];98:946–952. Available from: http://ahajournals.org.

[104] Lang C, Seyfang L, Ferrari J, et al. Do Women with Atrial Fibrillation Experience More Severe Strokes?: Results from the Austrian Stroke Unit Registry. Stroke [Internet]. 2017 [cited 2023 Feb 24];48:778–780. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.116.015900.

[105] Nielsen PB, Skjøth F, Overvad TF, et al. Female sex is a risk modifer rather than a risk factor for stroke in atrial fibrillation should we use a CHA 2 DS 2 -VA Score Rather Than CHA 2 DS 2 -VASc? Circulation [Internet]. 2018 [cited 2023 Feb 24];137:832–840. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.117.029081.

[106] Wu M, Rementer C, Giachelli CM. Vascular Calcification: an Update on Mechanisms and Challenges in Treatment. Calcif Tissue Int [Internet]. 2013 [cited 2022 Jul 23];93:365. Available from: /pmc/articles/PMC3714357/.

[107] Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol [Internet]. 2014 [cited 2022 Jul 23];34:715. Available from: /pmc/articles/PMC3975044/.

[108] Budoff MJ, Young R, Burke G, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J [Internet]. 2018 [cited 2022 Jul 25];39:2401. Available from: /pmc/articles/PMC6030975/.

[109] Vos A, Kockelkoren R, de Vis JB, et al. Risk factors for atherosclerotic and medial arterial calcification of the intracranial internal carotid artery. Atherosclerosis [Internet]. 2018 [cited 2022 Jul 25];276:44–49. Available from: http://www.atherosclerosis-journal.com/article/S0021915018312048/fulltext.

[110] Golüke NMS, de Brouwer EJM, de Jonghe A, et al. Intracranial artery calcifications: Risk factors and association with cardiovascular disease and cognitive function. Journal of Neuroradiology. 2022;49:281–287.

[111] Wu X, Wang L, Zhong J, et al. Impact of intracranial artery calcification on cerebral hemodynamic changes. Neuroradiology. 2018;60:357–363.

[112] Wang X, Chen X, Chen Z, et al. Arterial Calcification and Its Association With Stroke: Implication of Risk, Prognosis, Treatment Response, and Prevention. Front Cell Neurosci. 2022;16.

[113] O’Neal WT, Efird JT, Qureshi WT, et al. Coronary Artery Calcium Progression and Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging [Internet]. 2015 [cited 2022 Jul 26];8. Available from: /pmc/articles/PMC4681308/.

[114] Hillerson D, Wool T, Ogunbayo GO, et al. Incidental Coronary Artery Calcification and Stroke Risk in Patients With Atrial Fibrillation. AJR Am J Roentgenol [Internet]. 2020 [cited 2022 Jul 26];215:344. Available from: /pmc/articles/PMC7447556/.

[115] Wang TKM, Chan N, Cremer PC, et al. Incorporating coronary calcification by computed tomography into CHA2DS2-VASc score: impact on cardiovascular outcomes in patients with atrial fibrillation. EP Europace [Internet]. 2021 [cited 2022 Jul 26];23:1211–1218. Available from: https://academic.oup.com/europace/article/23/8/1211/6135353.

[116] Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet [Internet]. 2014 [cited 2023 Feb 23];384:1929. Available from: /pmc/articles/PMC4441266/.

[117] Alamowitch S, Turc G, Palaiodimou L, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. https://doi.org/101177/23969873221150022 [Internet]. 2023 [cited 2023 Feb 24];239698732211500. Available from: https://journals.sagepub.com/doi/10.1177/23969873221150022.

[118] Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J [Internet]. 2021 [cited 2023 Feb 24];6:I. Available from: /pmc/articles/PMC7995316/.

[119] Siller T, Chandratheva A, Bücke P, et al. Acute Stroke Treatment in an Anticoagulated Patient: When Is Thrombolysis an Option? Curr Treat Options Neurol. 2021;23.

[120] Meinel TR, Wilson D, Gensicke H, et al. Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants. JAMA Neurol. 2023;80:233.

[121] Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021.

[122] Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine. 2019;380:1326–1335.

[123] Bakkes J, Cheatle M, Mžavanadze N, et al. Annex I: Keeping the World’s Environment under Review. 2022;421–434.

[124] Shahjouei S, Tsivgoulis G, Goyal N, et al. Safety of Intravenous Thrombolysis among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. Stroke. 2020;533–541.

[125] Meinel TR, Wilson D, Gensicke H, et al. Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants. JAMA Neurol. 2023;80:233–243.

[126] Turc G, Bhogal P, Fischer U, et al. European Stroke Organisation (ESO) – European Society for Minimally Invasive Neurological Therapy (ESMINT) Guidelines on Mechanical Thrombectomy in Acute Ischaemic StrokeEndorsed by Stroke Alliance for Europe (SAFE). Eur Stroke J [Internet]. 2019 [cited 2023 Feb 24];4:6. Available from: /pmc/articles/PMC6533858/.

[127] Turc G, Tsivgoulis G, Audebert HJ, et al. European Stroke Organisation – European Society for Minimally Invasive Neurological Therapy expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischaemic stroke and anterior circulation large vessel occlusion. https://doi.org/101177/23969873221076968 [Internet]. 2022 [cited 2023 Feb 24];7:I–XXVI. Available from: https://journals.sagepub.com/doi/full/10.1177/23969873221076968.

[128] Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. New England Journal of Medicine [Internet]. 2018 [cited 2023 Apr 3];378:708–718. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1713973.

[129] Jovin TG, Saver JL, Ribo M, et al. Diffusion-weighted imaging or computerized tomography perfusion assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neurointervention with Trevo (DAWN) trial methods. International Journal of Stroke [Internet]. 2017 [cited 2023 Apr 3];12:641–652. Available from: https://journals.sagepub.com/doi/10.1177/1747493017710341.

[130] Kobeissi H, Ghozy S, Seymour T, et al. Outcomes of Patients With Atrial Fibrillation Following Thrombectomy for Stroke: A Systematic Review and Meta-analysis. JAMA Netw Open [Internet]. 2023 [cited 2023 Feb 24];6:e2249993–e2249993. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800111.

[131] Zdraljevi M, Pekmezovi T, Stanar cevi P, et al. Atrial fibrillation is associated with poor long-term outcome after mechanical thrombectomy for anterior large vessel occlusion stroke. 2022 [cited 2023 Apr 3]; Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106755.

[132] Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace [Internet]. 2021 [cited 2023 Aug 31];23:1612–1676. Available from: https://dx.doi.org/10.1093/europace/euab065.

[133] Chang PY, Wang WT, Wu WL, et al. Oral Anticoagulation Timing in Patients with Acute Ischemic Stroke and Atrial Fibrillation. Thromb Haemost [Internet]. 2022 [cited 2023 Oct 12];122:939. Available from: /pmc/articles/PMC9251709/.

[134] Oldgren J, Åsberg S, Hijazi Z, et al. Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy after Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study. Circulation [Internet]. 2022 [cited 2023 Aug 31];146:1056–1066. Available from: http://www.clinicaltrials.gov;

[135] Fischer U, Koga M, Strbian D, et al. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation. New England Journal of Medicine. 2023;388:2411–2421.

[136] Seiffge DJ, Hooff RJ, Nolte CH, et al. Recanalization therapies in Acute ischemic stroke patients impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome a pilot study. Circulation [Internet]. 2015 [cited 2023 Feb 24];132:1261–1269. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.115.015484.

[137] Seiffge DJ, De Marchis GM, Koga M, et al. Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. Ann Neurol [Internet]. 2020 [cited 2023 Aug 31];87:677. Available from: /pmc/articles/PMC7383617/.

[138] Ming Bonaventure Ip Y, Kai Lau K, Ko H, et al. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant. Neurology ®. 2023;101:358–369.

[139] Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J [Internet]. 2010 [cited 2022 Jul 22];31:967–975. Available from: https://academic.oup.com/eurheartj/article/31/8/967/544272.

[140] Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy: An ACTIVE W Substudy. J Am Coll Cardiol. 2007;50:2156–2161.

[141] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet [Internet]. 2009 [cited 2022 Jul 31];374:534–542. Available from: https://pubmed.ncbi.nlm.nih.gov/19683639/.

[142] Reddy VY, Doshi SK, Sievert H, et al. Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation. Circulation [Internet]. 2013 [cited 2023 May 14];127:720–729. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.112.114389.

[143] Holmes DR, Kar S, Price MJ, et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial. J Am Coll Cardiol. 2014;64:1–12.

[144] Reddy VY, Möbius-Winkler S, Miller MA, et al. Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation: The ASAP Study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61:2551–2556.

[145] Osmancik P, Herman D, Neuzil P, et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. J Am Coll Cardiol [Internet]. 2020 [cited 2022 Jul 31];75:3122–3135. Available from: https://www.jacc.org/doi/10.1016/j.jacc.2020.04.067.

[146] Nielsen PBSFRLHLTBLGY h. Utilization and Adverse Outcomes of Percutaneous Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation in the United States Influence of Hospital Volume. 2014 [cited 2022 Jul 31]; Available from: http://circep.ahajournals.org/lookup/suppl/doi:10.1161/CIRCEP.114.001413/-/DC1.

[147] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J [Internet]. 2021 [cited 2022 Jul 30];42:373–498. Available from: https://academic.oup.com/eurheartj/article/42/5/373/5899003.

[148] Whitlock RP, Vincent J, Blackall MH, et al. Left Atrial Appendage Occlusion Study II (LAAOS II). Canadian Journal of Cardiology. 2013;29:1443–1447.

[149] Zapolanski A, Johnson CK, Dardashti O, et al. Epicardial surgical ligation of the left atrial appendage is safe, reproducible, and effective by transesophageal echocardiographic follow-up. Innovations (Phila) [Internet]. 2013 [cited 2022 Jul 31];8:371–375. Available from: https://pubmed.ncbi.nlm.nih.gov/24346587/.

[150] Whitlock RP, Belley-Cote EP, Paparella D, et al. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. New England Journal of Medicine [Internet]. 2021 [cited 2023 Sep 29];384:2081–2091. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2101897.

[151] Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nature Reviews Cardiology 2017 14:11 [Internet]. 2017 [cited 2022 Jul 30];14:627–628. Available from: https://www-nature-com.liverpool.idm.oclc.org/articles/nrcardio.2017.153.

[152] Lip GYH, Ntaios G. “Novel Clinical Concepts in Thrombosis”: Integrated Care for Stroke Management-Easy as ABC. 2021 [cited 2023 Oct 12]; Available from: https://doi.org/.

[153] Proietti M, Romiti GF, Olshansky B, et al. Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease [Internet]. 2020 [cited 2023 Oct 12];9. Available from: /pmc/articles/PMC7660878/.

[154] Guo Y, Lane DA, Wang L, et al. Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. 2020 [cited 2023 Oct 12]; Available from: https://doi.org/10.1016/j.jacc.2020.01.052.

[155] Guo Y, Guo J, Shi X, et al. Mobile health technology-supported atrial fibrillation screening and integrated care: A report from the mAFA-II trial Long-term Extension Cohort. Eur J Intern Med [Internet]. 2020 [cited 2023 Oct 12];82:105. Available from: /pmc/articles/PMC7553102/.

[156] Scheitz JF, Nolte CH, Doehner W, et al. Stroke–heart syndrome: clinical presentation and underlying mechanisms. Lancet Neurol. Lancet Publishing Group; 2018. p. 1109–1120.

[157] Buckley BJR, Harrison SL, Hill A, et al. Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke. Stroke [Internet]. 2022 [cited 2023 Oct 12];53:1759–1763. Available from: https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.037316.

[158] Akyea RK, Georgiopoulos G, Iyen B, et al. Comparison of Risk of Serious Cardiovascular Events after Hemorrhagic versus Ischemic Stroke: A Population-Based Study. Thromb Haemost [Internet]. 2022 [cited 2023 Oct 12];122:1921–1931. Available from: http://www.thieme-connect.com/products/ejournals/html/10.1055/a-1873-9092.

[159] Lip GYH, Lane DA, Lenarczyk R, et al. Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke. Eur Heart J [Internet]. 2022 [cited 2023 Oct 12];43:2442–2460. Available from: https://doi.org/10.1093/eurheartj/ehac245.

[160] Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the “Atrial Fibrillation Better Care” Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients Stroke, Systemic or Venous Thromboembolism 406. Thromb Haemost [Internet]. 2022 [cited 2023 Oct 12];122:406–414. Available from: https://doi.org/.

[161] Musialek P, Rosenfield K, Siddiqui A, et al. Thrombosis and Haemostasis Carotid Stenosis and Stroke: Medicines, Stents, Surgery-"Wait-and-See" or Protect?

[162] Musialek P, Bonati LH, Bulbulia R, et al. Stroke risk management in carotid atherosclerotic disease: 1 A Clinical Consensus Statement of the ESC Council on Stroke and the ESC 2 Working Group on Aorta and Peripheral Vascular Diseases 3 4. [cited 2023 Oct 12]; Available from: https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvad135/7250075.

[163] Harrison SL, Buckley BJR, Lane DA, et al. Antiplatelet Agents and Oral Anticoagulant Use in Patients with Atrial Fibrillation and Carotid Artery Disease After First-Time Ischaemic Stroke. Cardiovasc Drugs Ther [Internet]. 2023 [cited 2023 Oct 14];1:1–7. Available from: https://link.springer.com/article/10.1007/s10557-023-07433-4.

[164] Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke Severity in Atrial Fibrillation. Stroke [Internet]. 1996 [cited 2023 Feb 19];27:1760–1764. Available from: https://www.ahajournals.org/doi/abs/10.1161/01.STR.27.10.1760.

[165] Suissa L, Bertora D, Lachaud S, et al. Score for the targeting of atrial fibrillation (STAF): A new approach to the detection of atrial fibrillation in the secondary prevention of ischemic stroke. Stroke [Internet]. 2009 [cited 2022 Jul 30];40:2866–2868. Available from: https://www-ahajournals-org.liverpool.idm.oclc.org/doi/abs/10.1161/STROKEAHA.109.552679.

[166] Malik S, Hicks WJ, Schultz L, et al. Development of a scoring system for atrial fibrillation in acute stroke and transient ischemic attack patients: The LADS scoring system. J Neurol Sci. 2011;301:27–30.

[167] Li Y-G, Bisson A, Bodin A, et al. C 2 HEST Score and Prediction of Incident Atrial Fibrillation in Poststroke Patients: A French Nationwide Study.

[168] Ntaios G, Perlepe K, Lambrou D, et al. External Performance of the HAVOC Score for the Prediction of New Incident Atrial Fibrillation. Stroke [Internet]. 2020 [cited 2022 Jul 30];457–461. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.119.027990.

[169] Kwong C, Ling AY, Crawford MH, et al. A Clinical Score for Predicting Atrial Fibrillation in Patients with Cryptogenic Stroke or Transient Ischemic Attack. Cardiology [Internet]. 2017 [cited 2022 Jul 30];138:133. Available from: /pmc/articles/PMC5683906/.

[170] Zhao SX, Ziegler PD, Crawford MH, et al. Evaluation of a clinical score for predicting atrial fibrillation in cryptogenic stroke patients with insertable cardiac monitors: results from the CRYSTAL AF study. Ther Adv Neurol Disord [Internet]. 2019 [cited 2022 Jul 30];12:1756286419842698. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31007721.

[171] Li YG, Pastori D, Farcomeni A, et al. A Simple Clinical Risk Score (C2HEST) for Predicting Incident Atrial Fibrillation in Asian Subjects: Derivation in 471,446 Chinese Subjects, With Internal Validation and External Application in 451,199 Korean Subjects. Chest [Internet]. 2019 [cited 2022 Jul 31];155:510. Available from: /pmc/articles/PMC6437029/.

[172] Alonso A, Krijthe BP, Aspelund T, et al. Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium. J Am Heart Assoc [Internet]. 2013 [cited 2022 Jul 30];2. Available from: https://www.ahajournals.org/doi/abs/10.1161/JAHA.112.000102.

[173] Christophersen IE, Yin X, Larson MG, et al. A comparison of the CHARGE–AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J [Internet]. 2016 [cited 2022 Jul 31];178:45. Available from: /pmc/articles/PMC5344697/.

[174] O’Neal WT, Alonso A. The appropriate use of risk scores in the prediction of atrial fibrillation. J Thorac Dis [Internet]. 2016 [cited 2022 Jul 30];8:E1391. Available from: /pmc/articles/PMC5107446/.

[175] Bugnicourt JM, Flament M, Guillaumont MP, et al. Predictors of newly diagnosed atrial fibrillation in cryptogenic stroke: a cohort study. Eur J Neurol [Internet]. 2013 [cited 2022 Jul 30];20:1352–1359. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/ene.12017.

[176] Kishore AK, Hossain MJ, Cameron A, et al. Use of risk scores for predicting new atrial fibrillation after ischemic stroke or transient ischemic attack—A systematic review. https://doi.org/101177/17474930211045880 [Internet]. 2021 [cited 2023 Feb 20];17:608–617. Available from: https://journals.sagepub.com/doi/10.1177/17474930211045880.

[177] McIntyre W. Protocol for a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to Prevent Stroke. Thromb Haemost [Internet]. 2023 [cited 2023 Oct 12];123:366. Available from: /pmc/articles/PMC9981276/.

[178] S C, J P, R H, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet [Internet]. 2006 [cited 2022 Jul 28];367:1903–1912. Available from: https://pubmed.ncbi.nlm.nih.gov/16765759/.

[179] Elijovich L, Josephson SA, Fung GL, et al. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis [Internet]. 2009 [cited 2022 Jul 28];18:185–189. Available from: https://pubmed.ncbi.nlm.nih.gov/19426887/.

[180] Amit  Kishore MAVMsAMMJDMKRLMPJTMCJSM. Detection  of  Atrial  Fibrillation  After  Ischemic  Stroke  or Transient Ischemic AttackA  Systematic  Review  and  Meta-Analysis. 2014; Available from: http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.

[181] Martin  Grond MMJMGHMESMRVMDNMMHMCWMMKMRWMLRMPKMF. Improved  Detection  of  Silent  Atrial  Fibrillation  Using  72-Hour  Holter  ECG  in  Patients  With  Ischemic  StrokeA  Prospective  Multicenter  Cohort  Study. 2013; Available from: http://stroke.ahajournals.org.

[182] Tayal AH, Tian M, Kelly KM, et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology. 2008;71:1696–1701.

[183] Ritter MA, Kochhäuser S, Duning T, et al. Occult atrial fibrillation in cryptogenic stroke: Detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke [Internet]. 2013 [cited 2022 Jul 28];44:1449–1452. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.111.676189.

[184] Israel C, Kitsiou A, Kalyani M, et al. Detection of atrial fibrillation in patients with embolic stroke of undetermined source by prolonged monitoring with implantable loop recorders. Thromb Haemost [Internet]. 2017 [cited 2022 Jul 29];117:1962–1969. Available from: https://pubmed.ncbi.nlm.nih.gov/28862284/.

[185] Sanna T, Diener H-C, Passman RS, et al. Cryptogenic Stroke and Underlying Atrial Fibrillation A BS TR AC T. N Engl J Med. 2014;370:2478–2486.

[186] Guo Y, Wang H, Zhang H, et al. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol. 2019;74:2365–2375.

[187] Perez M V., Mahaffey KW, Hedlin H, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal of Medicine [Internet]. 2019 [cited 2022 Jul 30];381:1909–1917. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1901183.

[188] Harrison SL, Buckley BJR, Zheng Y, et al. Evaluation of Huawei smart wearables for detection of atrial fibrillation in patients following ischemic stroke: The Liverpool-Huawei stroke study. 2022 [cited 2023 Oct 12]; Available from: https://doi.org/10.1016/j.ahj.2022.12.004.

[189] Sehrawat O, Kashou AH, Noseworthy PA. Artificial Intelligence and Atrial Fibrillation. J Cardiovasc Electrophysiol [Internet]. 2022 [cited 2023 Aug 31];33:1932. Available from: /pmc/articles/PMC9717694/.

[190] Rabinstein AA, Yost MD, Faust L, et al. Artificial Intelligence-Enabled ECG to Identify Silent Atrial Fibrillation in Embolic Stroke of Unknown Source. Journal of Stroke and Cerebrovascular Diseases [Internet]. [cited 2023 Aug 31];30:2021–105998. Available from: https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105998.

[191] Khurshid S, Friedman S, Reeder C, et al. Electrocardiogram-based Deep Learning and Clinical Risk Factors to Predict Atrial Fibrillation. Circulation [Internet]. 2022 [cited 2023 Aug 31];145:122. Available from: /pmc/articles/PMC8748400/.